MOUNTAINSIDE, NJ–(Marketwire – August 6, 2010) –  PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity. X Gen Medical has been established with the intention of conducting business in the global medical marketplace. Proteonomix plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide. It is anticipated that new relationships formed with X Gen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism. Medical tourism is constantly on the rise and anticipated to continue to grow substantially due to current high costs of health care for certain procedures and improvements in both technology and standards of care in many countries.

Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, “We have been in negotiations with several groups, specifically in the Middle East and Europe, to establish Proteonomix Regenerative Translational Medicine Institute (“PRTMI”) medical facilities in those regions. The negotiations have reached the level whereby the establishment of a separate subsidiary, X Gen Medical LLC., was essential in order to allow Proteonomix to properly enter these global markets with the intention of soliciting business through our proprietary PRTMI model. We anticipate closing on some of these negotiations in the near future, which we anticipate will include the necessary funding required to firmly establish X Gen Medical as a PRTMI provider.”

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements:
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Click here to see all recent news from this company

CLIFTON, NJ–(Marketwire – August 6, 2010) –  Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI) (www.ecsiinternational.com), a global leader in entry control and perimeter security systems, today announced the appointment of Robert Oliver as Vice President, Operations. 

Arthur Barchenko, President of ECSI, stated that “Robert will fill an important position in the Company to meet the growing demand for its products and services now and in the future. The position of Vice President, Operations will address product design and engineering, R&D, production scheduling, purchasing and inventory control in accordance with ISO 9001:2008.”

About Mr. Oliver
Robert Oliver brings decades of experience and innovation in engineering design and management to this position. He has successfully performed and managed the design, test, manufacturing, installation and maintenance of products and systems in avionics, nuclear power plant, power instruments, medical device, medical instruments, research instruments, surveillance and life safety for military, law enforcement, hospital, surgical, industrial, commercial and consumer markets domestically and internationally. He has functioned at all levels, including CEO. He has enjoyed successful deployment of security systems of his own design while working through AE firms such as Syska & Hennessey and Flack & Kurtz, among others, and for clients that include major banks and brokerage houses. He holds multiple patents in the US and elsewhere for industrial and security products and systems.”

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high profile, high threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, acceptance of our proposals, sufficiency of working capital, receipt and timing of collections from purchase orders, the availability of working capital, changes in economic conditions generally and in our industry specifically, changes in security technology, legislative or regulatory changes that affect us, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

LOS ANGELES, CA–(Marketwire – August 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF)

Dear Stockholder:

In the entertainment industry, 2012 was the name of a major motion picture. In China, 2012 will be the Year of the Dragon. At MMRGlobal, 2012 will be the Year of the Personal Health Record (PHR). That’s when health care professionals will be required to provide Personal Health Records to patients as part of compliance with Meaningful Use.

At MMRGlobal, we’re ready for the future of health care today.

The MyMedicalRecords.com PHR already offers patented Emergency Login features, patient selected privacy controls, the ability to securely receive and send a medical record from and to any health care professional (or anyone) anywhere in the world. And it does not matter how a record is created, with paper and pen or from the most sophisticated of EMRs. Further, the MMR Stimulus Program pays physicians for simply doing what they will have to do; specifically, electronically provide patients with timely access to their personal health information. Also, because we believe in the quality, safety and security of our product, MMR carries cyber liability insurance to protect our consumer and professional users from actual loss or damage caused by an error in the Company’s PHR system.

Last week in Chicago and yesterday in Los Angeles, we met with senior executives of two hospital systems representing more than 2,000 staff physicians. Working with these hospital systems, MMR is in the process of developing programs designed to enable hospitals and larger group practices to underwrite the installation of an MMRPro system through the MMR Stimulus Program.

Also last week in meetings at Kodak headquarters in Rochester, N.Y., we began planning on numerous expanded distribution strategies and joint sales and marketing opportunities. Additionally, this month we will begin testing the next generation of an MMRPro system with new Kodak hardware, improved software and a more seamless interface that will make it faster and more efficient for doctors’ offices to digitize patient records and offer MMRPatientView.com upgrades. We anticipate distributing the new MMRPro branded system later this year at which time we will upgrade any systems in the field at no cost to our customers.

Kodak will also promote the new MMRPro system in Kodak merchandising and marketing materials designed to make it easier for resellers and distributors to sell directly. We also will participate with Kodak in an expanded tradeshow schedule, with coverage in the Kodak newsletter and inclusion on Kodak’s Partner Web site. This quarter, National Payment Providers will also begin presenting MMRPro to its database of more than 160,000 physician billing clients with delivery and installation support from Kodak starting later this year. 

I also spent last week with Chartis International executives in New York regarding sales of MyEsafeDepositBox and MyMedicalRecords domestically. Rich Teich, MMRGlobal’s Executive Vice President, also attended preliminary implementation meetings in New York this week. We anticipate announcements on these and other similar programs in the first quarter of 2011 while we continue to push forward on the international front.

Later this month, expect the launch of the new redesigned MyEsafeDepositBox, which will be the structural backbone for Chartis Esafe and numerous banking programs, including one that has been in development for more than two years.

In China, we are deploying MMRGlobal developers in Zhengzhou City to work side-by-side with the local development teams at Unis-TongHe. They will begin design plans on the two projects for presentation to China’s hospital system. These proposal efforts represent the groundwork for two health information exchange systems that can provide services to over 100 million people. 

In October, I plan on visiting our technology partner Nihilent in India as part of a strategy to present MMR to government officials, private hospital networks and local health care professionals.

In addition to our ongoing efforts to identify a strategic partner to develop the Company’s anti-CD20 monoclonal antibody assets, we continue to look at our many other biotech assets arising out of the pre-merger Favrille Specifid vaccine and, as such, we are seeking opportunities with biotech and institutional investment partners to exploit those assets.

It is an extremely busy time at MMRGlobal. I have touched on a few of the many initiatives that this company is pursuing around the world. When the recently filed S1/A goes effective, the Company will have access to up to $10 million in capital which can help accelerate our ability to execute on these business opportunities and more. It will provide resources for development, marketing and sales of our products to our consumer, health care professional, corporate and affinity clients worldwide. As the largest beneficial holder of this company, I am excited about the fact that we will have these additional resources and look forward to being in a better position to execute on our plans and grow with the global health care market.

I rarely talk about the people on the MMRGlobal team and how they are the recipe for success. It’s two o’clock AM and I am working with Bobbie after 10 years and a full day of meetings with Rich (who I have worked with for 33 years), AJ (15 years), Ingrid (20 years) and Ralph (15 years), all of whom work around the clock seven days a week. 

Then there’s our Board of Directors. They also get to be on call 24-hours a day and utilize their entire network of contacts in support of the Company. For example, Hector Barreto has supported the Company for nearly three years after leaving as the longest running Administrator of the U.S. Small Business Administration. He presided over 9/11 and Katrina and brings with him a wealth of knowledge and experience.

George Rebensdorf has worked with me on finance and regulatory affairs for more than 15 years. Bernie Stolar, who I have worked with for nearly 30 years, brings the experience of launching Sony PlayStation®, running Sega and being the Gaming Industry Evangelist for Google. Also in the 30-year category is Jack Zwissig, who is an expert in executive leadership and corporate team building. Doug Helm, who was appointed to the board of pre-merger Favrille, is a world-class expert on insurance, benefits and banking and helps lead the Company’s insurance and banking efforts. Dave Boyden, another Favrille appointee, is the biotech answer man on the scientific assets in the Company’s portfolio.

There are not many people who can write about a team that’s been together for more than 175 years.

Sincerely,

Robert H. Lorsch
Chairman, President & Chief Executive Officer

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – August 6, 2010) – Zimek Technologies (www.zimek.com), the industry leader in infection control and biohazard remediation technology, today announced The Honorable Emil Jones Jr. has joined the company’s prestigious Advisory Board. From 2003-2009, Jones served as President of the Illinois State Senate, a position that culminated more than three decades of service in the Illinois legislature. Jones has been a mentor and friend to many politicians over the years including former Illinois State Senator Barack Obama with whom Jones served. Jones is currently a Senior Counselor at Mercury Public Affairs, leading the firm’s operations based in Chicago, Ill.

“Recognized as one of the most effective political leaders in Illinois state history, Emil Jones left an unparalleled legacy of achievement, making lasting contributions throughout the state, particularly in the areas of education, health care and criminal justice,” stated Kurt Grosman, CEO and President of Zimek Technologies. “We are extremely delighted he is joining our team. His contributions will be vital as we continue to spread the word that Zimek’s sophisticated three-dimensional touch-less decontamination technology can effectively defeat and prevent the spread of deadly viruses and bacteria.”

“Zimek’s automatic rapid decontamination and disinfection technology is a powerful addition to our arsenal of weapons to fight infectious diseases and biohazard attacks,” Senator Jones said. “Zimek’s technology can meaningfully help hospitals throughout our country improve infection control quality standards and ensure they use best practices to comply with new federal provisions issued by CMS (Centers for Medicare & Medicaid Services) which encourage hospitals to disclose and, proactively, reduce their healthcare acquired infections (HAIs). HAIs will now be tied to hospital Medicare reimbursement incentives.”

Jones joins other Zimek Advisory Board members including Dr. Brad Spellberg, scientist, researcher and infectious disease specialist at the David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center; Dr. Peder Bo Nielsen, consultant in Microbiology with the United Kingdom’s North West London NHS Trust; and Dr. Lindsey Shaw, Assistant Professor of Molecular Microbiology at the University of South Florida. (see http://www.zimek.com/advisoryboard.asp).

Zimek Technologies, based in Tampa, Florida, has been developing and marketing its patented automatic Micro-Mist™ decontamination technologies for more than five years. Zimek’s industry-leading technologies are used by the U.S. Department of Homeland Security, Fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities and local law enforcement agencies across America.

ISSAQUAH, WA–(Marketwire – August 6, 2010) –  A new simplified and easily accessible video format where the health care professional can go to obtain the latest in medical equipment and supply information and use has finally arrived: Qtube™.

According to one research study, 50% of online retailers in the US added video in some form last year, and 31% of Fortune 500 companies have public blogs that incorporate video blogging.

“Considering that 177 million Americans watch some sort of video online each month, and they saw 4.3 billion ads in June, it’s not surprising why we would add an educational video site,” said Scott Hanna, CEO at QuickMedical®. “With nearly 150 full feature product videos and educational clinics, QuickMedical® and Qtube™ can offer our customers an easy-to-use educational site where they can learn more about the latest in product development, use and technology.”

The majority of Qtube™ product and clinic video presentations are filmed on site at QuickMedical® in their state of the art display and video production room. A number of videos are also supplied to Qtube™ by the QuickMedical® vendor/manufacturers for review and placement on the Qtube™ site.

“Our video/media team put together a dynamic website that will feature future product promotions and will help the QuickMedical® vendors create and use new video content that will promote their goods and services,” said Tim Lightell, Social Media Coordinator at QuickMedical®. “Over a two day period, this June at our open house, we filmed nearly 150 vendor/product presentations and ten educational clinics, so there is a lot of content on the Qtube™ site.”

About QuickMedical® and Qtube™:

QuickMedical® has the professional medical equipment needed by health care providers. Look for diagnostic equipment, exam tables, weighing and measuring devices, and medical basics such as stethoscopes, thermometers, and sphygmomanometers. Qtube™ Videos are supplied by our manufacturers or produced in house by our Production Team. Most videos are shot in our state of the art showrooms. Current displays include medical, surgical, and a pediatric exam rooms. Look for QuickMedical’s® new television commercial, currently airing in the Seattle market on local ABC affiliate KOMO 4.

Click here to see all recent news from this company

MOUNTAIN VIEW, CA–(Marketwire – August 5, 2010) –  eHealth, Inc. (NASDAQ: EHTH), the nation’s leading online source of health insurance for individuals, families, seniors and small businesses, today announced that its senior management will present at Oppenheimer & Co. Inc.’s Annual Technology, Media & Telecommunications Conference on Wednesday, August 11 at 8:30 a.m. ET. This event will be held at the Four Seasons Hotel in Boston, MA.

Interested investors can access the live audio webcast of each presentation at www.ehealthinsurance.com under Investor Relations. Please visit the website at least 15 minutes early to register, download, and install any necessary software. A replay of each event will be available on the company’s website shortly after the conclusion of the event and will remain available for 14 days.

About eHealth, Inc.

eHealth, Inc. (NASDAQ: EHTH), the parent company of eHealthInsurance and PlanPrescriber, is the nation’s leading online source of health insurance for individuals, families, seniors and small businesses. Through the company’s websites (http://www.eHealthInsurance.com, http://www.PlanPrescriber.com and http://eHealthMedicare.com), consumers can get quotes from leading health insurance carriers, compare plans side by side, and apply for and purchase individual and family, Medicare, small group, short-term and ancillary health insurance products. eHealthInsurance is authorized by more than 180 of the nation’s leading health insurance companies and offers thousands of health plans. eHealthInsurance is licensed to sell health insurance in all 50 states and the District of Columbia, making it an excellent model of a successful, high-functioning health insurance exchange. Through its eCommerce On-Demand solution (eOD), http://www.ehealth.com/eOD/, eHealth is also a leading provider of on-demand e-commerce software services for health plan providers. eHealthInsurance and eHealth are registered trademarks of eHealthInsurance Services, Inc. PlanPrescriber is a registered trademark of PlanPrescriber, Inc.

CHICAGO, IL–(Marketwire – August 5, 2010) –  Titan Commercial today announces the completion of a lease for 9,620 square feet located at 1806 S. Highland Ave. in Lombard, Ill. Ben Rosenfield, principal of Titan Commercial, represented the tenant Health Resource Solutions (HRS) in their relocation and helped facilitate the transaction with landlord StoneCreek Properties, represented by Cawley Chicago Commercial. HRS executed a primary term of 10 years.

“With so much vacant space in the market, we wanted to ensure that we found the best deal, location and landlord to work with. Ben Rosenfield was an excellent resource and negotiated an amazing deal on our behalf that surpassed our expectations,” said Glenn Steigbigel, President of HRS.

Health Resource Solutions is a privately owned hi-tech home health company committed to serving healthcare professionals and patients. Open 365 days a year, HRS provides quality care for patients of all ages including hi-tech geriatric and pediatric nursing, physical therapy, occupational therapy, speech therapy, telemonitoring, and all other necessary coordinated services. They are currently located at 1700 W. Hubbard Street in Chicago. For more information visit the HRS website at www.healthrs.net.

Founded in 2007, Titan Commercial is a commercial real estate brokerage firm whose mission is to improve the lives beyond those involved in the negotiation. While specializing in the acquisition, disposition and leasing of commercial real estate properties, this full service firm has completed over $200 million in transactions and is active in representing landlords, tenants, sellers, purchasers and investors nationwide. Headquartered in Illinois, Titan Commercial also has an office in Arizona. For more information, visit www.titancommercialrealestate.com or call 312.373.7100.

Click here to see all recent news from this company

TORONTO, ONTARIO–(Marketwire – Aug. 5, 2010) – The John Howard Society of Toronto will be releasing ‘Homeless and Jailed: Jailed and Homeless;’ a report on the increasing number of homeless individuals in Toronto area jails who are being released to areas that are unable to provide sufficient resources to aid in reintegration and deter recidivism. John Howard researchers undertook 363 interviews with incarcerated individuals in 2009 and 2010. Among this group, 22.9 percent, or roughly one of every five prisoners, was homeless when incarcerated, that is they were staying in a shelter, living on the street (in places considered unfit for human habitation), in a treatment facility, or staying at the home of a friend, paying no rent. Overall, 32.2 percent, or almost one of every three prisoners had plans upon discharge to go to a shelter, live on the street, or couch-surf at the home of a friend. Another 12 percent of these prisoners are at risk of being homeless since they do not know where they will go.

The report will be released as part of Prisoners Justice Day activities at the Holy Trinity Anglican Church (10 Trinity Square – Bay and Queen – Behind the Eaton Centre) at 12:30pm on August 10^th. Prisoner’s Justice Day is an annual memorial day, dedicated to all those who have lost their lives while in custody.

Researchers Amber Kellen and Sylvia Novac will be among the presenters.

Email a Friend

Printer Friendly Version

Latest News Releases

DALLAS, TX–(Marketwire – August 5, 2010) – Metiscan’s (PINKSHEETS: MTIZ) majority owned subsidiary Schuylkill Open MRI, Inc. (Schuylkill), which is an outpatient diagnostic imaging facility located in Pottsville, Pennsylvania providing Magnetic Resonance Imaging (MRI) services, announced today that it has upgraded its legacy electronic healthcare records (EHR) system to a new Web 2.0 based Health Language Seven (HL7) compliant EHR and practice management system.

The new EHR system enhances practice workflow, improving operational efficiencies which management believes will increase cost savings and aid the center’s staff in providing high quality patient care. The EHR system enables Schuylkill to operate as a virtually paper free and filmless practice and includes features such as patient scheduling, practice management and the electronic archiving and distribution of high-quality MRI images and patient reports. Secure access is available to radiologists and referring physicians from any location having a web-browser and a broadband connection.

Schuylkill historically licensed the use of its former EHR system. Since 2003, Schuylkill has paid a licensing fee on a per-study basis. Going forward Schuylkill has determined to purchase its own EHR system and retain FirstView EHR, Inc. (FirstView), which is also a majority owned subsidiary of Metiscan, to host and administer the system. Purchasing the new EHR system provides Schuylkill with a productivity tool that embraces today’s latest secure web technologies and eliminates the need to pay a third party a license fee on a per-study basis.

About Schuylkill Open MRI, Inc.
Schuykill Open MRI, Inc. (Schuylkill) is an outpatient diagnostic facility located in Pottsville, Pennsylvania providing Magnetic Resonance Imaging (MRI) services. Schuylkill began operations in March 2003 and currently performs MRI exams on a Siemens OPEN MRI platform and a Siemens 1.5T high-field MRI platform. Having both platforms provides Schuylkill flexibility in the studies it can conduct. Schuylkill participates in most major insurance plans and accepts Medicare, Medicaid, Worker’s Compensation claims, Personal Injury Protection (PIP) and Letters of Protection (LOPs). Schuylkill is accredited by the American College of Radiology (ACR) and is a majority owned subsidiary of Metiscan, Inc. 

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Click here to see all recent news from this company

CENTERVILLE, MA–(Marketwire – August 5, 2010) – UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is very pleased to announce that it has received an order from specialized indoor air quality distributor Puravair for a shipment to the prestigious Miami Anatomical Research Center (“M.A.R.C.”) located in Miami, Florida (www.marctraining.com).

M.A.R.C. is one of the finest medical technology training facilities in the country, offering world class surgical training for a variety of specialties. It is one of the few places in the country offering as many as forty, state-of-the art bio skill lab stations in a hospital style setting alongside custom designed conference and lecture facilities delivering full videoconferencing in a dedicated facility. The introduction of new technologies and medical devices requires constantly evolving expertise and the centre offers training to a huge and skilled market of medical specialists encompassing North, Central and South America, as well as the Caribbean. 

“This order is significant when you consider the client’s needs and perspective,” stated Jack Lennon, President of UV Flu Technologies. “They are an internationally-respected medical facility that instructs a diverse client list of doctors, surgeons and other talented practitioners of the medical profession from throughout the western hemisphere.”

“We trust that other teaching facilities, at home and abroad, will take note and quickly identify that our product offers a cost effective and easy to implement method to increase the overall safety level of any facility by immediately lessening the risk of airborne bacteria, and one that also limits the spread of noxious odors and Volatile Organic Compounds (‘VOC’),” said Mr. Lennon, as he further comments, “The ViraTech UV-400 is specifically designed to kill dangerous strains of bacteria which may present themselves from time to time, while also reducing the levels of other contaminants and odors from the air we breathe.”

Mr. Lennon concluded by saying, “Here is a sale which clearly demonstrates product penetration into a massive market encompassing all forms of medical teaching facilities, as well as businesses such as funeral homes and working pathology labs worldwide. The potential list of users in this sector is huge.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

MARINA DEL RAY, CA–(Marketwire – August 5, 2010) –  Marijuana Incorporated (PINKSHEETS: PCIO) (http://www.marijuana-incorporated.com) and Medical Marijuana, Inc. (PINKSHEETS: MJNA) has been galvanized by the New Rasmussen Poll showing 75% of Americans support the use of Medical Marijuana by Adults if prescribed by a physician, up from 63% last October. This number clearly shows that a large majority believes in the efficacy of Cannabis, and is an indication that the 14 States and the District of Columbia, recognizing Medical Marijuana were on the right course in fulfilling the will of their citizens.

“We see these numbers as a ‘Tipping Point,'” stated CEO Bruce Perlowin. “More states that are currently in the process of Legalization efforts will certainly come into the fold and it is also interesting to note that the Poll showed that 95% believe that it is likely that Marijuana will be fully legalized in the next 10 years.

Furthermore, Rasmussen shows that the California Bill to Tax and Regulate Cannabis, Prop 19, has 52% approving while opposed by only 36% indicating strongly that recreational Marijuana will be legal in California in November. Additionally, the City of Detroit is also voting this November to legalize recreational Marijuana.

These facts underscore the decision by PCIO to apply for and receive a name change to “Marijuana, Inc.” and jump into this quickly emerging multi-billion dollar industry. With several divisions being created in Marijuana, Inc., from 420 friendly resorts, to licensing the rights of Medical Marijuana, Inc.’s (PINKSHEETS: MJNA) attractive logo for an entire clothing line, Marijuana, Inc. is positioning itself to be a leader and trend setter in the medical marijuana, cannabis, hemp and related peripheral industries.

About Marijuana, Inc.

Marijuana Inc., a Colorado corporation, is one of the first and most prolific distributors in “The Hemp Network.” The Hemp Network is a division of our sister company, MJNA. Marijuana Inc. invites those that would like to capitalize on this fast growth industry to become a part of The Hemp Network by logging onto http://www.thehempnetwork.com using first name “Marijuana” last name “Inc” and phone # 239-738-0434; 239-738-0434. The company is also the first to develop “420” friendly resorts, through the acquisition of a new division. The company continues to market the world’s most expensive coffee, like the one described in the movie with Morgan Freeman, “The Bucket List,” and this civet coffee will be available in the company’s “420” resorts. Marijuana Inc. has also entered into an agreement to acquire certain marketing rights for a clothing line from Medical Marijuana Inc. and if the agreement is consummated, PCIO will issue shares to MJNA and/or its shareholders.

Forward-Looking Statements

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.

SAN FRANCISCO, CA–(Marketwire – August 4, 2010) – Find the AAAnswers, a multi-faceted public education campaign designed to raise awareness of abdominal aortic aneurysms (AAA) and drive at-risk individuals to be screened, today announced the launch of a podcast and video series. Find the AAAnswers developed the series as an alternate avenue to educate consumers about AAA risk factors, and encourage at-risk individuals to be screened for the disease.

Podcast segments will cover a range of topics including:

• AAA survivor stories from patients and family members
• AAA in the news
• Tips for prevention and management of the disease

The first podcast in the series is currently available at http://www.slideshare.net/FindtheAAAnswers/podcast-1 and features a discussion with Find the AAAnswers Coalition partners Dr. Thomas Maldonado and Karen Fitzgerald, NP. Dr. Maldonado, a representative of Peripheral Vascular Surgery Society (PVSS), is also Chief of Vascular Surgery at Bellevue Hospital and Associate Professor of Surgery at NYU School of Medicine. He will provide listeners with an overview of AAA, explain who is potentially at-risk for the disease, and why it is known as a silent killer. Fitzgerald, a member of the Society for Vascular Nursing and Director of Nursing for The Vascular Group, PLLC, discusses the process of an AAA screening, how to discuss AAA with a loved one, and where to turn for more resources.

New podcast segments will be added monthly and available for download on www.FindtheAAAnswers.org and additional audio channels including iTunes and Podcast Alley. 

The first Find the AAAnswers webisode launched today and features impromptu, “man-on-the-street” style interviews with passersby in San Francisco to assess their level of awareness of AAA. Upcoming videos in the series will include behind the scenes looks at local AAA screening events and one-on-one chats with Campaign spokesperson and NFL legend, Joe Theismann. New videos will be added to the series monthly, and available for viewing on the Campaign’s YouTube channel.

Both series will also provide consumers with an opportunity to interact with Find the AAAnswers spokespersons, medical experts and AAA survivors by allowing them to submit their own questions to be posed in upcoming episodes.

About the Find the AAAnswers Campaign
Find the AAAnswers is a multi-faceted public education campaign designed to raise awareness of abdominal aortic aneurysms (AAA) and drive at-risk individuals to be screened. The campaign is supported by the Find the AAAnswers Coalition, an alliance of concerned medical societies, including the American College of Preventive Medicine, Peripheral Vascular Surgical Society, Society for Vascular Nursing, Society for Vascular Surgery and Society for Vascular Ultrasound.

Medtronic, Inc. provides sponsorship for the program due to the lack of awareness and accurate information available to the millions of at-risk Americans. Former professional football quarterback and sportscaster, Joe Theismann serves as the campaign’s spokesperson due to his family history of AAA.

• Follow us on Twitter
• Like us on Facebook
• Visit our YouTube channel
• Get updated AAA information with our widget

id=”nav_links”>

WEST HARTFORD, CT–(Marketwire – August 4, 2010) –  ORLive, the vision of improving health, presents a live broadcast of one of the newest total knee systems on the market presented by Wright Labs. Also explore the capabilities available at Morgan Stanley Children’s Hospital’s Center for Prenatal Care, as its world renowned staff presents its capabilities. In addition to these videos, ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board, and go back to school this month as your watch and learn from this month’s featured channel of medical education content.

NEW ON ORLIVE

LIVE SURGERY VIDEO – EVOLUTION™ Medial-Pivot Knee System
Live Monday, August 2, 2010, 6:00 PM EDT

Designed to replicate the function of a normal knee, the EVOLUTION™ Medial-Pivot Knee is one of the newest total knee systems on the market. This surgery is performed by Dr. David DeBoer, and he’ll answer questions during the broadcast. Learn the latest on the knee system that was built utilizing state-of-the-art design and manufacturing technologies… don’t miss “EVOLUTION™ Medial-Pivot Knee System.”

This surgery video is available to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND – Prenatal Pediatrics
Now Available On-Demand

Managing a high risk pregnancy can be difficult. NewYork-Presbyterian Morgan Stanley Children’s Hospital provides the maternal, fetal and pediatric expertise to care for high-risk pregnancies. NewYork-Presbyterian Morgan Stanley Children’s Hospital was one of only eight hospitals in the country ranked in each medical specialty measured by U.S. News & World Report, with distinct leadership in neonatology and pediatric cardiac surgery.

Join Dr. Mary D’Alton, Chair, Department of OB/GYN, Columbia University College of Physicians and Surgeons, and a team that includes Dr. Richard Polin, Director, Neonatology, as they review the capabilities and treatments available at the Center for Pediatrics. 

Viewers of this video are invited to interact with the team via the ORLive website, and to join the community and receive regular updates from the NewYork-Presbyterian Morgan Stanley Children’s Hospital Center for Neonatal Pediatrics.

ORLIVE REFERRALS – Week of August 2, 2010
Each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Access to Surgical Intervention for Metabolic Syndrome and Other Diseases from Synovis Life Technologies

CME Referral: The New Frontiers in Atrial Fibrillation from CMEducation Resources

Viewer’s Referral: Webinar Series: Leading Causes of Life Among Those Who Care for Others from Methodist University Hospital

HIGHLIGHTS

NOW ON-DEMAND – Total Thoracoscopic Maze
Now Available On-Demand

The total thoracoscopic maze is a surgical procedure intended to permanently cure atrial fibrillation. This minimally invasive, beating heart procedure will be performed by Dr. Mubashir Mumtaz, Chief of Cardiothoracic Surgery at PinnacleHealth. 

Viewers are still invited to interact with the surgical team by submitting questions via the ORLive website. To learn more about this broadcast go to ORLive.com.

PREVIEW – DePuy® Rotating Platform Revision Knee Replacement
Live August 12, 2010, 7:00 PM

Dr. Russ Nevins will perform a revision total knee replacement using the Sigma® TC3 RP and M.B.T. Revision Tray system from DePuy Orthopaedics, Inc. The broadcast will be moderated by Dr. William Barrett (Renton, WA). This broadcast will take place from Spring Valley Hospital Medical Center in Las Vegas, NV. 

At 4PM Pacific (7PM EDT), Dr. Nevins will perform the revision total knee replacement surgery featuring the Sigma TC3 RP, a rotating platform knee implant design. This system helps diffuse loosening forces from the increased mechanical constraint typical in revision implant systems and offers surgeons enhanced fixation options through the use of metaphyseal sleeves on the femoral and tibial side. 

Viewers are invited to interact with the surgical team by submitting questions via the ORLive website. To learn more about this broadcast and to sign up for an e-mail reminder go to ORLive.com.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

NEW YORK, NY–(Marketwire – August 4, 2010) –  MedLink (OTCBB: MLKNA), a leading provider of Electronic Health Records and practice management solutions, is pleased to announce the acquisition of Health Informatics, Inc. a provider of cutting edge clinical data digitization technology that simplifies and streamlines the adoption of Electronic Health Records. 

The Health Informatics Digital Pen, in conjunction with MD Form Manager, is the flagship offering of the Company. The Digital Pen looks and feels like a normal ball point pen, however, the Digital Pen contains an integrated infrared digital camera, an advanced image microprocessor and a mobile communications device for wireless connection. The camera records the precise location of ink strokes as it moves over a uniquely constructed grid of microscopic dot patterns. These dots provide the pen with exact co-ordinates of its position, which, through MD Form Manager, are designed to interface directly with the MedLink EHR to collect discrete data elements that electronically populate the patient chart. The solution provides doctors and their staff with the traditional documentation approach of pen and paper, but the advanced ability of digitally documenting and capturing the data required to provide ‘meaningful use’ and other quality data reports.

Ray Vuono, President of MedLink, stated, “We partnered with Health Informatics a little over three months ago to offer the Digital Pen and the immediate reception to the technology in the marketplace was overwhelming. Both parties immediately realized the potential and the overall benefits of a combined solution and we’ve worked diligently over the past few months with Health Informatics to move beyond the inherent limitations of a partnership. The MD Form Manager and Digital Pen provides MedLink with a significant competitive advantage and I’m very excited to welcome Mr. Sayed Alam to the MedLink team, who I’m sure will be one of our most valuable assets. Mr. Alam, the President of Health Informatics, in addition to building a technology platform and enterprise offering, provides MedLink with a wealth of Industry knowledge, foresight and business acumen.”

About Health Informatics

Health Informatics provides cutting edge technology for the automated digitization of patient clinical forms. The solution eliminates the need for a separate digitization process and the associated time and expense involved with traditional paper medical records, by seamlessly integrating digital form with Electronic Health Record (EHR) systems. Please visit www.healthinformatics.us.com, to learn more about the technology and offerings.

About MedLink

MedLink is a healthcare IT company that provides the medical community with products and services designed to help create, manage, and share medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-K available through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

MOUNTAIN VIEW, CA–(Marketwire – August 4, 2010) – Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible medical robotics and the developer of robotic technology for accurate 3D control of catheter movement, today reported its recent business highlights and financial results for the second quarter ended June 30, 2010.

Recent Business Highlights

• System Sales: The company recognized revenue on seven Sensei® Robotic Catheter Systems and shipped three systems during the second quarter. Second quarter revenue consisted of one system that was shipped in the quarter and six systems from deferred revenue that had been shipped in prior quarters. From commercial launch in 2007 through June 30, 2010, the company has shipped a cumulative total of 91 Sensei systems worldwide and recognized revenue on a total of 77 systems.
• Catheter Sales: The company recognized revenue on 555 Artisan^™ Control Catheters shipped during the second quarter.
• Procedures: Electrophysiology procedures performed with Hansen Sensei systems increased over 50% in the first half of 2010 as compared to such procedures performed in the first half of 2009.
• Vascular Platform: The company announced the successful completion of a pre-clinical in-vivo study evaluating its new vascular robot, which demonstrated improvements in catheter navigation, reduction in vessel trauma during catheter manipulation, and improvements in access time for some vessels, as compared to manual catheter manipulation during endovascular procedures. Results also showed that the company’s vascular robot has the potential to standardize catheter navigation, which may lead to more predictable procedures. The early, but encouraging results were presented June 12, 2010 at the Society of Vascular Surgery’s 2010 Vascular Annual Meeting in Boston.
• Electrophysiology: The company announced a joint development and cooperation agreement with Siemens Healthcare to co-develop integrated products designed to help simplify complex cardiac procedures for the diagnosis and treatment of cardiac arrhythmias, or irregular heartbeats. The agreements will enable the creation of integrated product solutions by combining Siemens’ Artis zee® family of angiography systems and the syngo® DynaCT Cardiac (angiographic computed tomography) with Hansen Medical’s Sensei® X Robotic Catheter System. The integrated products are being designed to enable electrophysiologists to perform complex cardiac procedures with greater confidence and improved efficiency.
• Clinical Trial Update: During the second quarter, enrollment began in the company’s conditional IDE clinical trial evaluating use of the Sensei® Robotic Catheter System and the Artisan^™ Control Catheter in patients with Atrial Fibrillation (AF).
• On June 9, 2010 veteran medical device industry executive Bruce J Barclay joined the company as president and chief executive officer, and a member of the Board of Directors. In addition, Frederic H. Moll, M.D. became executive chairman of the Board and Russell C. Hirsch, M.D., Ph.D., transitioned from his former role as chairman of the Board to lead outside director.

“The company is making important progress on several fronts that include key initiatives in growing our EP business, developing and commercializing our vascular platform and improving our operating efficiency,” said Bruce Barclay, president and chief executive officer of Hansen Medical. “During the second quarter, we commenced a previously announced conditional IDE clinical trial using our Sensei Robotic Catheter System for the treatment of patients with AF and results from a recently completed pre-clinical in-vivo study evaluating our new vascular robot validate the important progress of our vascular platform in addressing significant new markets for the company. Finally, while the company successfully raised $29.8 million of capital early in the second quarter, we are continuing to take a hard look at operating expenses while maintaining our focus on our strategic key initiatives.”

2010 Second Quarter Financial Results

Total revenue for the three months ended June 30, 2010 was $7.0 million compared to revenue of $2.9 million in the same period in 2009. During the second quarter, the company recognized revenue on seven Sensei Robotic Systems as well as on shipments of 555 Artisan control catheters. During the quarter the company shipped a total of three systems; one of which was recognized as revenue and two of which will be recognized as revenue as they are installed and physicians are trained, which the company expects will occur during 2010. In addition, six systems from deferred revenue that had been shipped in prior quarters were recognized as revenue in the second quarter of 2010. As of June 30, 2010 the company had a total deferred revenue balance of $10.3 million. The company has shipped 14 Sensei systems that have not been recognized as revenue.

Cost of goods sold for the three months ended June 30, 2010 was $4.5 million and included non-cash stock compensation expense of $156,000. As a result, gross profit for the quarter was $2.5 million and gross margin was 35.7%. This compares to gross profit of $0.3 million and gross margin of 9.7% for the same period in 2009, which included non-cash stock compensation expense of $214,000. Looking ahead for the remainder of 2010, the company expects that cost of goods sold, both as a percentage of revenue and on a dollar basis, will continue to vary from quarter to quarter as manufacturing levels fluctuate and as revenues fluctuate due to changes in system and catheter sales volumes, the timing of revenue recognition on shipped systems, product mix and average sales prices per system and per catheter.

Research and development expenses for the three months ended June 30, 2010, including non-cash stock compensation expense of $372,000, were $6.1 million, compared to $5.0 million for the same period in 2009, which included non-cash stock compensation expense of $688,000. The increase in research and development expenses was primarily the result of development of the company’s vascular system platform. During the remainder of 2010, the company expects research and development expenses to increase from 2009 levels principally due to the on-going vascular system platform development, the atrial fibrillation clinical trial sponsored by the company and engineering activities to support the fiber optic shape sensing and localization technology under our Luna Innovations development agreement.

Selling, general and administrative expenses for the three months ended June 30, 2010, including non-cash stock compensation expense of $504,000, were $7.2 million, compared to $9.9 million for the same period in 2009, which included non-cash stock compensation expense of $1.0 million. The decrease in selling, general and administrative expenses was primarily due to decreased employee-related expenses, related primarily to lower average headcount and a decrease in non-cash stock compensation expense. During the remainder of 2010, the company expects selling, general and administrative expenses to decline from 2009 levels primarily as a result of a decrease in legal and restatement-related expenses.

Other expense, net, for the three months ended June 30, 2010 was $131,000, compared to other expense, net, of $115,000 for the same period in 2009.

Net loss for the three months ended June 30, 2010, including total non-cash stock compensation expense of $1.0 million, was $10.9 million, or $(0.22) per basic and diluted share, based on average basic and diluted shares outstanding of 50.1 million shares. Net loss for the second quarter of 2009, including non-cash stock compensation expense of $1.9 million, was $14.7 million, or $(0.42) per basic and diluted share, based on average basic and diluted shares outstanding of 35.2 million shares.

Cash, cash equivalents and short-term investments as of June 30, 2010 were $44.2 million, compared to $28.3 million as of December 31, 2009. The higher cash, cash equivalents and short-term investments balance is primarily due to the successful completion of a secondary public offering of common stock in the second quarter of 2010, which included the sale of approximately 16.1 million shares with net proceeds to the company, after expenses, of approximately $29.8 million.

Hansen Medical Conference Call

Company management will hold a conference call to discuss its 2010 second quarter results today, August 4, 2010, at 2:00 p.m. Pacific (5:00 p.m. Eastern). Investors are invited to listen to the call live via the Internet using the link available within the “Investor Relations” section of Hansen Medical’s website at www.hansenmedical.com. A replay of the webcast will be available approximately one hour after the completion of the live call. Additionally, participants can dial into the live conference call by calling 888-549-7750 or 480-629-9867. An audio replay will be available approximately one hour after the completion of the conference call through August 11, 2010, by calling 800-406-7325 or 303-590-3030, and entering access code 4333050.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company’s robotic navigation system enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. Hansen Medical’s Sensei® system and its Sensei X Robotic Catheter System are compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. The remote navigation platform was cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. The safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hansen’s results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “believes,” “goal,” “estimate,” “enable” and similar words. Hansen intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in such statements due to various factors, including but not limited to: the effect of credit, financial and general economic conditions on capital spending by our potential customers; risks and uncertainties inherent in our business, including potential safety and regulatory issues that could delay, slow or suspend our clinical trial or our sale efforts, uncertain timelines, costs and results of clinical trials and of developing new products, our ability to effectively sell, service and support our products, the rate of adoption of our systems and the rate of use of our catheters at customers that have purchased our systems, our ability to plan and manage cost-reduction or operational efficiency initiatives, the scope and validity of intellectual property rights applicable to our products and competition from other companies; additional costs and resources necessary to address existing shareholder litigation regarding the restatement of our financial statements; potential claims and proceedings relating to our restatement, such as additional shareholder litigation and any action by the SEC, U.S. Attorney’s Office or other governmental agency which could result in civil or criminal sanctions against the company and/or current or former officers, directors or employees; our ability to remediate material weaknesses in internal controls over financial reporting; and other risks more fully described in the “Risk Factors” section contained in Hansen’s periodic SEC filings, including its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2010.

“Sensei,” “Artisan,” and “CoHesion” are trademarks of Hansen Medical, Inc., and “Hansen Medical,” “Hansen Medical and Heart Logo,” and “Hansen Medical Heart Logo” are registered trademarks of Hansen Medical, Inc. in the United States and other countries. Artis zee and syngo are registered trademarks of Siemens AG.

Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)

Condensed Consolidated Balance Sheets (unaudited)
(in thousands)

NEW YORK, NY–(Marketwire – August 4, 2010) –  The need to reduce hospital costs is driving sales of new wound care products, even advanced products with a higher price tag, according to healthcare market research publisher Kalorama Information. Innovations such as biotechnology, biomaterials and tissue engineering will continue to boost revenues, according to its recent report “World Wound Care Markets 2010.” Kalorama estimates the worldwide wound care market reached revenues of $14 billion in 2009 and expects annual growth of over 6% for the next few years.

There have been many research developments in the acceleration of wound healing over the last decade. However, recently these advancements are taking place even more frequently and some of the new products now represent the best new change in the past 30 years. New developments are providing the health care arena of today with some truly sophisticated, highly effective wound care treatments that are poised for growth.

“Many of these new products are proven cost-savers,” said Mary Ann Crandall, analyst for Kalorama Information and author of the report. “There’s always a demand to reduce hospital stays and improve patient outcomes, and a product that can save money in the long run can get a favorable result in reimbursement decisions.”

Wound healing is much like solving a puzzle that involves a series of integrated physiological processes. Various steps must be synchronized and organized in order for everything to fall into place. Without the proper signals at the correct time, a wound cannot heal properly. Having the right tools available, such as appropriate cells, proper nutrition and proper support, is essential. The nature of healing is the same for all wounds with variations depending on the location, severity, and extent of injury. More sophisticated products and a better understanding of the healing processes are increasingly helping to better solve this puzzle.

Beyond new products, Kalorama predicts the market will expand into the future due to demographic factors such as an aging population and an increasing number of sicker patients with more complex coexisting illnesses including diabetes, heart failure, obesity, pulmonary and vascular diseases, immobility issues and chronic wounds. Pressures to cut costs and move patients out of hospitals faster are also leading manufacturers to develop more effective wound care products, according to the report.

The top four wound care companies worldwide include Johnson & Johnson, Kinetic Concepts, Hill Rom and Smith & Nephew. These companies are responsible for about 60% of the revenues of the total market.

“World Wound Care Markets 2010” investigates what the wound care market looks like today; how the market has fared during the recent economic downturn; which segments offer the best market opportunity for companies; and many other key issues and trends. For further information visit: http://www.kaloramainformation.com/redirect.asp?progid=79420&productid=2675467.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

SUNRISE, FL–(Marketwire – August 4, 2010) –  Interim HealthCare® Inc., the nation’s first and finest healthcare and in-home senior care franchise company, is offering Philadelphia residents the opportunity to own their own business with an Interim HealthCare franchise. With a network of more than 300 independently owned franchises across the country, Interim is now seeking franchisee candidates in Philadelphia to be part of an aggressive growth campaign designed to increase its U.S. presence over time. 

Interim’s senior care franchises include non-medical and medical personal care, nursing and healthcare staffing services. The system has a 40 year history within the healthcare industry and many of their franchisees have an average tenure of 24 years.

Executives from Interim will be in town to host a franchise opportunities seminar on August 17 at 7:00 p.m. at the Crowne Plaza – Valley Forge located on 260 Mall Boulevard for all interested candidates. To register for the event and learn more, please log onto www.interimfranchising.com or call 866-767-4730.

“Interim HealthCare has been assisting patients and their families since 1966 and we are excited to expand our footprint in Philadelphia,” said Kathleen Gilmartin, CEO of Interim Healthcare. “We’re looking for interested individuals to join our team who have the sensitivity and compassion needed in our business to help our customers when it matters most.”

Currently with more than15 locations in Pennsylvania, Interim is looking to expand its presence throughout the state by indentifying eight new openings in Philadelphia over four years. Qualified candidates should possess a minimum net worth of $400,000, and a minimum liquidity of $50,000. Franchisees can expect their initial investment to range from approximately $115,500 to $188,500 including the franchise fee.

“Today there are 1 in 8 people 65 or older and by 2030 there will be more than twice that number,” said Gilmartin. “Therefore the growing senior population and home care growth market is a great niche for franchising and with additional Interim HealthCare franchises in the Philadelphia area, we will help the increasing need,” said Gilmartin.

Franchisees utilize comprehensive operations, financial, training, and sales systems to assist in operating their business at maximum efficiency and effectiveness. Additionally, they receive extensive local and national marketing support throughout the year. Interim HealthCare franchise owners share a commitment to improving the lives of their patients and communities, and they continue to realize opportunities for growth in the growing baby boomer segment and home care industry.

About Interim HealthCare:
Founded in 1966, Interim HealthCare® is the nation’s oldest proprietary national health care franchise organization providing health care personnel at all skill levels in all settings. Through a comprehensive network of more than 300 independently owned franchise offices, Interim HealthCare® franchisees are the largest combined provider of community-based home care (skilled and non-medical) and health care staffing. Interim HealthCare is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service through franchisees who employ more than 75,000 health care workers who serve 50,000 people each day. For more information or to locate an Interim HealthCare office, visit www.interimhealthcare.com.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – August 4, 2010) –  Bivar, a leading specialty provider of LED indication products and solutions, today announced ORCAdapt™ a complete light pipe system. The new system arms design engineers with a host of options that make moving LED light in existing and emerging applications much easier. The new ORCAdapt solution consists of an ORCA adaptor with a built-in ORCA Super Flux LED and a flexible light pipe system available in 1mm or 2mm size options.

The ORCAdapt unites the well-known brightness and durability of the ORCA Super Flux LED with the optimized light transmission and customized routing of Bivar’s flexible light pipe systems. Bivar’s ORCAdapt is ideally suited for a wide variety of applications such as field instrumentation, heavy equipment, medical devices and transportation.

“The new ORCAdapt brings together a solution that features our ORCA Super Flux LEDs and our 1mm and new 2mm flexible light pipe system,” said Michael Finn, Bivar vice president of sales and marketing. “The ORCAdapt is our answer to customer demand for a complete, cost-effective light pipe system that offers a greater level of design freedom with brilliant light output and high performance.”

The new ORCAdapt light pipe system features Bivar’s ORCA series of Super Flux LEDs, which are an expansion of the company’s high power LEDs designed for use on standard printed circuit boards. ORCA Super Flux LEDs offer greater luminous intensity, higher power efficiency and additional lens configurations while maintaining an industry standard 7.6mm square package form factor. In addition, ORCAdapt supports Bivar’s 1mm and 2mm flexible light pipe systems. The 2mm plastic optical fiber light pipe system is Bivar’s newest addition to the light pipe family and is an ideal LED indication alternative to custom rigid light pipes. The optical fiber maximizes light transmission up to 98 percent, has no light leakage, and is covered with a tough, flexible RoHS compliant PVC alloy outer jacket that maximizes light transmission.

Additional features of the ORCAdapt Complete Light Pipe System:

• Available in lengths from 2.5″ to 238′;

• Works with single, bi-color and tri-color ORCA LEDs;

• Input driven color adjustment capabilities;

• Simple press fit lens mounting provides rapid installation while retention is vibration and shock resistant.

The new ORCAdapt is immediately available. For more information please visit www.bivar.com. For application assistance and samples, please contact Bivar Sales at [email protected].

About Bivar
Bivar is a leading specialty provider of LED indication products and solutions with a long-standing history of more than 40 years of innovation in the optoelectronics industry. With a global base of customers in 35 countries, Bivar’s products are designed to meet the increased demand for point-to-point indication and address a growing range of industrial markets and applications. Bivar’s focus is on moving and positioning light. An employee-owned company, Bivar’s corporate headquarters are located in Southern California, with manufacturing in California, China and Taiwan. 

Bivar’s Asia Pacific production and logistics centers offer scalable capacity, execution, control and movement of product around the world. Bivar is widely supported by a highly qualified network of authorized representatives and distributors. For more information, please visit www.bivar.com.

Click here to see all recent news from this company

MIAMI, FL–(Marketwire – August 4, 2010) –  Renato Corporation (FRANKFURT: 4OZ) is pleased to announce the merger with a major pharmaceutical group in California and Texas as well as 8 medical clinics in California and Arizona. Due diligence has just completed and we look forward to the closing of the merger within the next 14 days.

Healthcare in the United States is undergoing a profound change, driven by both legislation and cost. The new healthcare legislation, the excessive cost of American Health Care, and an estimated 35 million more people under the healthcare will drive the growth of medical clinic groups.

The 8 medical clinics have a combined revenue of $10.5 million dollars.

This group operates 20 natural pharmacies in southern California and Texas and has annual revenues in excess of $8 million, targeted primarily at the Hispanic market, the fastest growing segment of the US population, with vitamins, nutraceuticals and wellness products, the fast growing category of consumer consumption.

The merger of the health clinics with the natural pharmacies is an ideal mix that is designed to enhance the bottom line of both operations with a blend of Hispanic and Non Hispanic clientele.

The established revenues of the properties plus the expected growth of the merged entity will ensure the success of Renato Corporation. The company is in serious discussion with a further 8 groups comprising 27 clinics with revenue in 2010 of approximately $65 million and EBITDA of $14.5 million.

The incoming board comprises Bob Pritchard as Chairman as well as Marketing Director with Dwight Staffelback, BA, MS Public Administration, who will take on the position as CEO, and John Falting is taking up position as Company Secretary for the group.

As of August 2, 2010, the new Board of Directors of Renato Corporation is re-structuring the company’s corporate business plan and is evaluating all existing negotiations and agreements.

www.renatocorp.com, www.renatocorp.de

About Renato Corporation

At Renato Corporation it is the company’s objective to provide diverse early detection diagnostic technologies utilizing its current experience, reputation and expertise within the international health care industry. Introducing and making available these non-invasive technologies through private health care firms and health and wellness centres in an affordable manner is our immediate focus.

The company’s mission is to carefully select where these advanced diagnostic technologies will be placed to ensure unparalleled delivery of customer service and satisfaction in the field of non-invasive early detection disease diagnosis and management.

Innovative information technology platforms are enabling new models for more efficient, effective and safer healthcare delivery. It is inevitable that the economic strain on today’s health care systems worldwide will realize the ever increasing need for early detection diagnostic devices and services.

Disclaimer & Safe Harbor Statement:
This release includes forward looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise. “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – August 4, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced the decision to close
the US headquarters of NicOx Inc. with effect from August 31, 2010. The
decision follows a review of the Group’s structure and requirements after
the US Food and Drug Administration (FDA) said it could not approve its
lead drug candidate naproxcinod, which is expected to at least
significantly delay any potential US launch.

NicOx plans to discuss possible next steps as early as possible with the
FDA and to continue to pursue the European regulatory process for
naproxcinod. NicOx will also actively seek to enter into partnerships for
naproxcinod in Europe and the rest of the world as well as for other
products in its pipeline whilst also pursuing appropriate in-licensing and
M&A opportunities.

The Company had cash and cash equivalents of ?128.4 million at June
30, 2010, and no long-term debt. It also has development partnerships on
its pipeline with Bausch + Lomb, Merck & Co. Inc and Ferrer Grupo.

Michele Garufi, Chief Executive Officer of NicOx, commented: “We very much
regret having to close our operations in the US and we are grateful for the
hard work and dedication of all our employees over the past few years. They
have played a major role in raising awareness among scientists and
clinicians of naproxcinod’s potential medical and clinical value. As we
seek to work out possible next steps for naproxcinod in the US and to
pursue the approval process in Europe, it is essential that we manage our
resources in the most effective manner.”

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of NicOx S.A. to
differ from those contained in the forward-looking statements, please refer
to the Risk Factors (“Facteurs de Risque”) section of the Document de
Reference filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

This information is provided by HUGIN

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 3, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (“ALDA” or “the Company”) announces that it is seeking an extension of the exercise period of an aggregate of 6,000,000 outstanding share purchase warrants issued as part of the non-brokered private placement of common share units which closed on September 16, 2009. Pursuant to the proposed extension, the applicable exercise period will be extended by one further year, from September 16, 2010 to September 16, 2011. The warrant exercise price of $0.40 per share will remain the same. Insiders of the Company hold 50,000 of the outstanding share purchase warrants subject to the proposed amendment.

The proposed extension is subject to the warrant holders entering into definitive amendment agreements and the acceptance of the TSX Venture Exchange. The amendment provides ALDA with an extended opportunity to receive funding for general corporate purposes from existing warrant holders.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

DENVER, CO–(Marketwire – August 3, 2010) –  Microsoft recently published a case study demonstrating how executives at Denver Health increased performance and strategic focus using Microsoft Outlook and productivity models developed by McGhee Productivity Solutions (McGhee).

The case study describes a situation where executives at the helm of a large hospital serving 25 percent of Denver’s population found themselves spending too many hours trying to manage the influx of messages and meeting requests that flow through the medical center each day. Chief Information Officer at Denver Health, Gregory Veltri, stated, “I was working 12-hour days and spending about three and a half hours per day on just e-mail.”

McGhee provided desk-side productivity coaching to executives and their assistants to increase their strategic focus, performance, and work/life balance. The program provided proven theories and models for improving knowledge-worker efficiency, creating behavioral change, and implementing an Integrated Management System using Microsoft Outlook. Results included a more powerful partnership, reductions in non value-added tasks, and an increase in time spent on objectives. As recorded in the case study, the executives and their assistants have reclaimed time and gained control of their workday with positive shifts in overall accountability and integrity.

Veltri, who previously found it difficult to find the time to plan for departmental growth, now spends much more time planning and developing the IT strategy for his team and for Denver Health. “I can consistently assess how my team’s goals contribute to the overall strategy and make timely adjustments as necessary,” stated Veltri following the coaching.

All Denver Health participants in the McGhee coaching program have said that their ability to balance work and their personal lives has improved significantly. Executives improved planning, strategic focus, boosted their daily productivity, and are now able to spend more time on strategic tasks. When they were asked to quantify the improvement, employees and senior management reported increased satisfaction rates of up to 20 percent.

“The strategic partnership between Microsoft and McGhee goes back several decades. Our collective offerings complement each other to drive business results for enterprise clients, and we are very proud of our work with Denver Health and this acknowledgement,” said McGhee CEO, Sally McGhee.

Read the full case study at http://www.mcgheepro.com/executive-management-productivity-strategies-case-studies.aspx

McGhee Productivity Solutions, Inc. (McGhee) provides consulting services, tools, and education to increase performance and work/life balance. Based in Denver, CO, McGhee integrates its proven methods and protocols with Microsoft technology to deliver innovative action-management strategies to individuals, teams, and organizations worldwide. From the boardroom to the knowledge worker, the McGhee approach drives accountability, maximizes technology investments, and improves job satisfaction to help organizations create a true culture of productivity. McGhee is in the process of becoming a Certified Woman-Owned Business www.mcgheepro.com.

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – August 3, 2010) – Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors and caregivers in the Chicago area who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Sunday, August 22 at 9:00 a.m. at Northerly Island (formerly Meigs Field), just south of Adler Planetarium and east of Soldier Field.

What are the qualifications to participate?
Participants need to be breast cancer survivors or healthcare workers and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

NEW YORK, NY–(Marketwire – August 3, 2010) –  A robust over-the-counter (OTC) drug market exists in less developed regions, where OTC is often the most practical distribution method, according to medical market research publisher Kalorama Information. According to “The Worldwide Over-the-Counter (OTC) Drug Market,” a recent Kalorama report, non-prescription pharmaceutical sales account for between 8% and 30% of total pharmaceutical markets around the globe, with higher ratios of OTC sales in developing nations. Kalorama estimates the OTC drug market in Asia-Pacific and Africa is worth $21 billion with an average growth of 4% annually.

In 2009, the OTC drug market in the developing BRIC nations (Brazil, Russia, India, and China) claimed a higher percentage of total pharmaceutical sales compared to more developed nations such as the United States, which had an OTC market share of 8%. India paced the quartet of burgeoning world powers with an OTC market share of 33%. China (23%), Russia (19%), and Brazil (17%) followed suit with double-digit OTC share claims.

Developed nations Japan and Australia are also important international players in the OTC market, though the greatest opportunities for growth and expansion remain in China, India, Singapore, Malaysia, and Indonesia, among other developing nations.

“It’s simply easier to work around regulatory and distribution issues in these countries by distributing product direct to consumers where it is medically possible,” said Melissa Elder, analyst for Kalorama Information. “It’s not a new trend, but we see sales to developing nations continuing to drive up the portion of all Pharma sales that are OTC.”

Additionally, in nations such as China the general population has an increasing ability to purchase products due to staggering increases in per capita Gross National Income between 2000 and 2005. Combined with the large population of China, there is now a more significant market opportunity for companies to sell products, especially OTC products. In comparison, the U.S. experienced a mere fraction of China’s per capita GNI growth during the same period, while Latvia was the only country with a greater GNI increase than China.

The state of the economy, lifestyles, cultures, and the condition of medical care all contribute to the percentage of people that seek to self-medicate. People are highly influenced by the cost of healthcare and will purchase OTC products in order to save money. Because a large number of consumers in India are uninsured, the majority of the population is forced to be conscious of health spending. As an example the report says that nearly 80% of India’s population actively self-medicates according to the report. In Kenya nearly 60% of the population actively self-medicates for similar reasons.

“The Worldwide Over-the-Counter (OTC) Drug Market” investigates the strategies pharmaceutical companies are using in the international OTC market. The report includes market sizes and forecasts in five general segments. For further information visit:
http://www.kaloramainformation.com/redirect.asp?progid=79415&productid=2661910.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

WESTPORT, CT–(Marketwire – August 3, 2010) –  Save the Children deployed its rapid response team to the worst-affected and hardest to reach communities in Pakistan’s Swat Valley, where record-breaking monsoon rains have triggered deadly floods and mudslides. The team had to navigate the rushing waters using rafts linked to ropes and pulleys in order to distribute temporary shelters and supplies to stranded children and their families.

The Information Minister of the worst affected province of Khyber Pakthunkhwa, Mian Ifthikar Hussain, estimates 1,500 have been killed by the floods nationwide. Now, officials fear an outbreak of disease among the millions left homeless and without clean water supplies. 

“In nearly all the flood-affected areas, water supplies have been contaminated,” said Annie Foster, Save the Children’s associate vice president for humanitarian response. “There are confirmed reports of diarrhea and cholera that may spread rapidly among the hundreds of thousands who have lost their homes. In this type of environment, children — especially those under five years of age — are the most vulnerable to severe illness and even death.”

Save the Children sent mobile health teams to provide emergency medical aid to treat more than 1,400 people in DI Khan, Buner and the Swat Valley area. The teams travelled by boat and often had to hike many kilometers to remote villages, where roads and bridges had been washed away.

The floods are now heading towards Muzaffargarh, Layyah and DG Khan and Rajanpur, in Punjab. Heavy rains predicted for the first two weeks of August are expected to increase the difficulty of delivering humanitarian aid.

“People are stranded and are rapidly using up their supplies of stored food,” said Foster. “There is a critical need to get more clean water, food and medical assistance to thousands of children and their families in the next few days.”

Save the Children has been working with the children of Pakistan and their families for more than 30 years, and provided assistance to those affected by Tropical Storm Phet in June, the conflict in Khyber-Pakhtunkhwa Province in 2009 and the massive earthquake in 2005.

Donate Now to the Pakistan Children in Emergency Fund or call (800) 728-3843.

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and around the world. 

NEWPORT BEACH, CA–(Marketwire – August 3, 2010) –  Nationwide Health Properties, Inc. (NYSE: NHP) announced today that its Board of Directors declared a quarterly common stock cash dividend of $0.46 per share, a $0.01 increase from the prior quarterly dividend of $0.45 per share. The dividend will be paid on September 3, 2010 to stockholders of record on August 20, 2010.

Nationwide Health Properties, Inc. is a real estate investment trust (REIT) that invests primarily in healthcare real estate in the United States. As of June 30, 2010, the Company’s portfolio of properties, including mortgage loans and properties owned by unconsolidated joint ventures, totaled 628 properties among the following segments: 283 senior housing facilities, 206 skilled nursing facilities, 120 medical office buildings, 11 continuing care retirement communities, 7 specialty hospitals and 1 asset held for sale. For more information on Nationwide Health Properties, Inc., visit our website at http://www.nhp-reit.com.

NEW YORK, NY–(Marketwire – August 3, 2010) –  United Treatment Centers, Inc. (PINKSHEETS: UTRM)

Dear Fellow shareholders:

It has been three months since the company has issued a press release and we, UTRM management, wanted to inform investors on the progress of the company’s business plan.

The company was notified that Glaxo Smithkline had filed a trademark infringement lawsuit which precluded the advisability of shipping any product with the contested name. There was no way of knowing how long the legal process would be, and weeks became months. The company is diligently working to resolve the issue with Glaxo and will inform investors on any progress immediately. “We feel this lawsuit has only delayed the company’s ability to ship product and will ultimately be finalized,” said Todd Spinelli Vice President of Business Development. He added, “This proprietary product brings sanitary brushing, convenience and the first ever waterless toothbrush to the forefront of a 47 Billion Dollar global industry.”

The company continues to pursue contracts and business relationships in anticipation of the resolution of the lawsuit. The company has ordered product parts without the “Aquafree” name to fulfill any new orders and will announce any shipments. UTRM management does not feel that the success of the Waterless Toothbrush is dependent upon the “Aquafree” name and is anxious to move forward in following up with promising initiatives with a number of government agencies and international distributors.

UTRM has discovered, and is targeting, a very promising sector for the Waterless Toothbrush in the United States — municipalities in states that face severe challenges with water conservation initiatives.

Significantly for the long term future of UTRM, the company has been approached by well-known retail merchants but it has been determined that it would be advisable that the company “grow” into accepting these larger orders from these large potential customers. Financing larger orders too early in the company’s financial history can be limiting and restrict our flexibility, but we anticipate closing on these larger accounts in the next six to twelve months.

UTRM management is confident that our business plan is solid and the company will continue to sign contracts with significant marketing partners within the next few weeks. We apologize for the inadvertent delays in executing our business plan, but we are excited by the future of the company and our groundbreaking product. We already know there is a great deal of interest by green technology firms, governmental and non-governmental organizations (NGO’s) and international distributors.

As shareholders too, we understand your frustration with recent delays, but we thank all shareholders for their patience and support. You can visit us at www.thewaterlesstoothbrush.com

Sincerely,
UTRM Management

To be included in the company’s database for company updates, press releases and industry developments, investors and shareholders should send their e-mails to [email protected].

About United Treatment Centers, Inc.
UTRM is a dental health and green technology company which developed and is now marketing a revolutionary new, patented and patent pending oral care product which will change the way people perform their daily dental hygiene task-brushing teeth. UTRM will oversee out-sourced production of a patent pending consumer product focused on the $4.8 billion United States oral care market segment comprised of toothbrushes and toothpaste. The Waterless Tooth Brush is unique with significant advantages over existing and traditional toothbrushes: it cleans and prevents cavities 35% better than traditional brushing because it uses liquid dentifrice (Journal of American Dental Association [JADA:135(7): pp.1023-1029]), so toothpaste is no longer required to brush, allowing the user to brush virtually anywhere at any time with no water required. The company’s corporate website is http://www.unitedtreatmentcenters.com/.

This document includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or beliefs, and are subject to uncertainty and changes in circumstances changes in economic, business, competitive, technological and/or regulatory factors.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

SOUTH SAN FRANCISCO, CA–(Marketwire – August 3, 2010) –  Two leading non-profit providers of mental health and addiction recovery counseling services are merging their organizations to provide better care and more comprehensive, holistic counseling to those in need, it was announced today.

Pyramid Alternatives of Pacifica, which provides counseling on mental health, substance abuse, domestic violence, and trauma services, will merge with Sitike Counseling Center of South San Francisco, a provider of addiction recovery services. The merged organizations will continue to be housed in their respective locations in Pacifica, South San Francisco, San Bruno and Half Moon Bay.

Rhonda Ceccato, executive director of Sitike Counseling Center, believes that by combining the two organizations, those in need will get more comprehensive, holistic counseling. “Two years ago, Janeen Smith and I began talking about our mutual concerns for the future,” she said. “The economic climate and the challenges of serving a more diverse and complex population, together with the need to attract and retain qualified staff, drove us to seriously consider a merger.”

Janeen Smith, executive director of Pyramid Alternatives, explained that the merger will result in better care for the organization’s clients. “Our new organization will be an important safety net for the San Mateo community, providing valuable services to an especially vulnerable population in this economy,” said Smith.

Ceccato and Smith both believe that the increasing emphasis on co-occurring or complex disorders as well as the desire among funders for larger, more comprehensive providers makes the merger a logical progression. An added benefit for staff will be the opportunity for quality training and career advancement. No layoffs are planned at this time, said Ceccato and Smith.

When the merger is completed, Rhonda Ceccato will serve as Executive Director and Janeen Smith will be Deputy Director. The respective Boards of both organizations will be combined to form a single Board of Directors.

Pyramid Alternatives has been serving clients in San Mateo County since 1973 and Sitike Counseling Center first opened its doors in 1988. The newly merged group will announce its new name by December 2010.

Rhonda Ceccato has more than 30 years of experience in the San Francisco Bay Area’s non-profit sector. Substance abuse treatment is both her passion and her area of expertise. Since 1993, Rhonda has served as Executive Director of Sitike Counseling Center, a community-based treatment center that provides a variety of recovery services for adult men and women. In 1995 Rhonda co-founded the San Mateo County Alcohol and Drug Providers’ Coalition, which recently merged with the San Mateo County Mental Health Contractors to form the Behavioral Health & Recovery Contractors Association. Prior to beginning her tenure at Sitike, Rhonda was Executive Director for the San Francisco Chapter of the National Council on Alcoholism and Drug Dependence and from 1977 to 1992 Rhonda worked in various capacities, including Interim Executive Director for the Women’s Alcoholism Center in San Francisco. She played a key role in planning and designing the Bay Area’s first intensive outpatient and residential programs for pregnant and parenting women, Lee Woodward Counseling Center and Pomeroy House. Rhonda Ceccato was elected in 2002 to the San Mateo County Board of Education and serves as a Trustee for South San Francisco Unified School District. Rhonda also lends her expertise as an active participant in other community organizations and currently serves as a consultant to the Nurse Diversion Evaluation Board for the State of California Board of Registered Nursing.

Janeen Smith is a Licensed Marriage and Family Therapist (MFT) with 20 years of experience in the field of mental health, substance abuse and violence prevention. She began her career in residential treatment at Bay Area Youth Centers in Hayward, California, in 1991. In 1995, she began work as a Case Manager for Edgewood Children’s Center in San Francisco after which she joined the Counseling Clinic at San Francisco State University. In 1997, she interned at Rape Trauma Services in Burlingame and began work at Pyramid Alternatives and has been there ever since. While at Pyramid, Janeen began as a staff counselor, was promoted from Outpatient Coordinator to Alternatives to Violence Manager and when licensed, became a clinical supervisor. In 2006, she was promoted to Deputy Director, and finally took over as Executive Director in 2007. Janeen’s passion is in partnerships and collaboration to improve services to the community. She is a co-founder of the North County Outreach Collaborative, (NCOC), and a co-founder of the Bayshore Community Prevention Project. Janeen is a member of the Co-Occurring Steering Committee of San Mateo County, the Daly City Partnership and Pacifica Collaborative. Janeen received a Masters of Counseling degree from San Francisco State University and her Bachelor of Science degree from San Diego State University.

Sitike Counseling Center
306 Spruce Avenue
South San Francisco, CA 94080
650-589-9305
www.sitike.org

Pyramid Alternatives
480 Manor Plaza
Pacifica CA 94044
650-355-8787
www.pyramidalternatives.org

Click here to see all recent news from this company

VICTORIA, BRITISH COLUMBIA–(Marketwire – Aug. 3, 2010) – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm” or the “Company”) today announced that it has entered into a loan agreement and general security agreement with MD Primer Inc. (“MDP”) under which MDP has agreed to extend to CardioComm a $200,000 line of credit secured against CardioComm’s assets, which CardioComm may use on an as-needed basis as it continues to implement its 2010/2011 business strategies. Any amounts drawn by CardioComm on the line of credit will bear simple interest at 6% per year and will be repayable on or before July 28, 2012. MDP is under the direction of Dr. Anatoly Langer, CardioComm’s Chairman. As MDP is a related party of CardioComm, Dr. Langer abstained from voting on the transaction when the transaction received board approval.

CardioComm also announced an amendment to its GEMS 4.0 software development agreement with MDP, dated November 1, 2009 and announced in a November 16, 2009 press release, involving the development and release of a new, multi -language compatible software platform of the GlobalCardio™, GEMS™ GEMS™ Air/HL7/Auto Attendant modules and other pipeline software systems. CardioComm was resticted to a five year time frame to purchase exclusive software rights. The amendment removes CardioComm’s purchase restriction clause, while continuing CardioComm’s perpetual, non-exclusive license to the software.

“With this amendment, we remain on track for our most significant software release which will keep us in step with emerging wireless technologies, and expansion into international markets. In addition, CardioComm is able to review its co-license agreement with MDP at its discretion,” reports Etienne Grima, CardioComm’s CEO.

The Company also announced that it granted an aggregate of 750,000 incentive stock options pursuant to its Omnibus Share Compensation Plan as follows: 500,000 options were granted to Etienne Grima, the Company’s CEO; and 250,000 options were granted to Wendy Hsieh, the Company’s CFO. The options are exercisable at $0.10 per share for five years from the date of grant, will vest equally over a period of 18 months and are subject to a four month hold period. The grant of options will be subject to the provisions of the Company’s Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

About CardioComm Solutions, Inc.

CardioComm’s patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company’s products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm’s software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Anatoly Langer, Chairman of the Board

SEATTLE, WA–(Marketwire – August 3, 2010) –  Mindbloom, Inc. today announced a strategic partnership with Sacramento State ‘s health and wellness facility, also known as The WELL (Wellness, Education, Leisure, Lifestyle), that will leverage Mindbloom technology to enhance the effectiveness of the campus’ 7 Dimensions of Wellness Program. 

The Well serves approximately 28,000 faculty, staff and students and is designed to support health-promoting behaviors and healthy life-balance choices. Mindbloom’s enterprise platform enables The WELL to insert its proprietary content into the Mindbloom platform to create a customized experience that encourages users to make their healthy behaviors an everyday priority.

“The WELL’s program is a perfect fit for our enterprise platform,” said Chris Hewett, Mindbloom’s founder and executive producer. “By fusing great content within an easy-to-use format, we’ve created a wellness and personal development experience that’s simple, fun and effective. The combination of the university’s framework and our Life Game™ platform will deeply engage students, faculty and staff in ways that can actually establish and sustain healthy habits.” 

Mindbloom.com is a social Life Game — a new genre of online experiences that motivate and activate people in their quest for health and wellness, life balance and meaningful relationships. By combining proven personal development concepts with gaming mechanics and social networking support, Mindbloom creates an immersive, personalized, online experience where users choose and accomplish small steps that produce meaningful results. Its enterprise platform allows content providers, wellness programs, and health-oriented communities to embed the Mindbloom experience into their own website, customize their users’ experience, incorporate their proprietary content, and extend both their core philosophy and their brand.

“Incorporating the Mindbloom enterprise platform takes our 7 Dimensions of Wellness Program to a higher level,” said Mirjana Gavric, director of The WELL. “It helps us personalize our information and its experiential engagement and social networking support make it a perfect fit for the members of the Sacramento State community.”

Mindbloom Launches Enterprise Platform

The WELL at Sacramento State is a 151,000-square-foot-facility that’s scheduled to open September 2, 2010. Its 7 Dimensions of Wellness Program helps participants explore and balance all aspects of their lives, toward creating and maintaining optimal wellness. 

“Mindbloom’s enterprise platform is an important part of our business model,” said Brent Poole, Mindbloom’s CEO. “Partnering with academically grounded and well developed programs like The 7 Dimensions of Wellness allows us to connect with people who have decided they want to take more responsibility for their own health, and who want a little extra help to take small steps toward things that they care about.” 

Because the Mindbloom experience is effective in motivating and supporting people to make and sustain personal change, Mindbloom’s enterprise platform will be attractive to any company, association, organization, or community seeking to support its members to make personal change toward healthier lifestyles. It is an excellent business solution for corporate wellness companies, employee benefit departments, health systems, insurance networks, and wellness programs. 

About Mindbloom

Mindbloom, Inc. is located in Seattle, Wash. and was founded in 2008. The company provides an online service, The Mindbloom Life Game™, which offers an interactive, fun and rewarding way to focus priorities around health and wellness. The service includes components of casual gaming, social networking and personal media sharing. It was built by former executives and developers from Amazon, Monolith, AOL, Microsoft, Vulcan and Adobe. Users have found Mindbloom to be an effective way to manage personal intentions and goal setting. The mission of the company and the game itself is to inspire and motivate people to live a healthy, balanced and meaningful life. Mindbloom offers a free-to-play version which requires the user to “earn” their way through the experience and a Professional version in which users are able to add content (actions, images, goals) at will. There are currently two subscription levels for this service priced at $39/year or $89 for a lifetime. Mindbloom also offers completely customized and white-label solutions for enterprise organizations. For more information, please visit www.mindbloom.com

About The WELL at California State University, Sacramento

The WELL will be a 151,000-square-foot multi-use facility with multi-activity courts, weight and fitness rooms, climbing wall, indoor track, and a new student health center. Sacramento State students will be able to exercise, participate in group recreational activities, access healthcare services, study and socialize. The WELL mission statement, “Lifetime wellness through collaboration, education and innovation sets the tone for a renewed and vibrant campus life. It will also be a resource for faculty and staff as it offers a host of cutting-edge fitness, recreation, and athletic opportunities. For more information about The WELL, please visit http://www.thewell.csus.edu/

BETHESDA, MD–(Marketwire – August 3, 2010) – GetWellNetwork, Inc. today announced that Comer Children’s Hospital at the University of Chicago is using GetWell Town™, the industry’s leading pediatric interactive patient care solution, to advance patient engagement, education and safety. GetWell Town is also helping children ease into their hospital stay with high quality entertainment features including password-protected, parent-controlled access to the Internet, Pandora, Hollywood movies, games and more. 

“GetWell Town is the perfect bedside solution to complement our vision of children and family-centered care,” said Jeffrey Finesilver, Vice President of University of Chicago Medical Center and Director of Comer Children’s Hospital. “We are very excited to provide our families and young patients with a new interactive approach to learning about their health and to access the hospital’s resources from the bedside.”

One of the first initiatives at the hospital has been to provide patients and families with direct access to services such as housekeeping, patient relations, hospital chaplain and more. Rather than calling their nurse to make service requests, patients can simply use their beside remote control and keyboard to communicate their needs via the GetWell Town system. This streamlines service requests, expedites the response, frees nurses for care tasks, and empowers young patients to feel independent and make their own choices.

GetWell Town offers exclusive KidsHealth® content with more than 170 videos of specific conditions and medical procedures — all in child-friendly language.

Comer Children’s Hospital will be enhancing patient education and influencing clinical outcomes through innovative programs such as the GetWell Town Asthma Care Plan. The GetWell Town Asthma Care Plan prepares patients and families for managing their condition at home with fewer visits to the hospital.

GetWellNetwork will also integrate with the hospital’s EpicCare Inpatient Clinical System to enable bi-directional flow of patient information. Nurses will be able to order education content specific to a child’s diagnosis, keep track of their progress and have it automatically documented into the patient’s record. This will help save nursing hours, meet regulatory compliance, and reduce the potential for human errors.

“Comer Children’s Hospital is focused on providing the optimal patient care experience for their patients and families.” said Shannon O’Neil, MSW, Director of Pediatrics, GetWellNetwork, Inc. “We are honored to be working with them in leveraging bedside technology to truly educate and engage families throughout the care process, and to help in driving key hospital initiatives.”

About GetWell Town
GetWell Town was developed in collaboration with GetWellNetwork’s National Children’s Hospital Task Force, comprised of 15 pediatric facilities across the U.S. as well as direct input from pediatric patients and their families. GetWell Town is designed to complement the kid-friendly spaces that children’s hospitals have worked hard to create and features exclusive content in partnership with KidsHealth®, part of The Nemours Foundation’s Center for Children’s Health Media.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

LIVINGSTON, NJ–(Marketwire – August 3, 2010) –  A newly published report underscores the importance of technology and skilled technique in the practice of preimplantation genetic diagnosis (PGD). PGD has been a hotly debated topic in recent years due to the inconsistent conclusions from numerous trials.

Downloadable photos and other supporting materials available here: http://www.multimedianewscenter.com/reprogenetics/new-report-bolsters-support-for-pgd

The paper, published in the July issue of Fertility and Sterility, identifies numerous factors that contribute to the procedure’s success. Data show that PGD success appears to correlate with access to the appropriate technology and the level of skill and technique used by the embryologists.

“Our analysis of available research shows that clinics using optimal methodology, highly skilled technicians and the most advanced chromosomal assessment techniques have consistently shown an improvement in assisted reproductive technology results with PGD,” said Santiago Munné, Ph.D., founder of Reprogenetics and one of the nation’s leading experts on PGD. “PGD remains a viable option for many couples who are at risk of passing on certain genetic diseases to their children or who have been unsuccessful with assisted reproduction to help increase their chance of having a healthy baby.”

In his review, Dr. Munné identified that widely varying biopsy and chromosome analysis procedures were used, leading to conflicting results. Additionally, poor training and limited experience in these delicate procedures may also contribute to reduced embryo implantation following PGD.

According to Dr. Munné, the formula for successful PGD includes: Identifying the appropriate patient by considering maternal age and evaluating the number of embryos available, using an experienced laboratory with trained scientists reduces the risk of not obtaining a result, taking a biopsy of a single cell from the embryo, processing of the cell appropriately, analyzing a minimum of eight important chromosomes as well as working with a PGD laboratory that has an error rates below 10% with extensive experience and showing positive outcomes in PGD. 

The technique used to analyze the extracted chromosomes may play an important role in embryo selection. Array comparative genome hybridization (array CGH) is a newer technique capable of accurately determining total or partial abnormalities affecting any of the 24 different types of chromosomes, compared to more traditional FISH testing which analyzes just 5-12 chromosomes. Data presented at the last American Society of Reproductive Medicine meeting demonstrated that using CGH analysis resulted in a highly statistically significant increase in implantation rates in women with an average age of 38 and with one to 10 prior failed IVF cycles.

About PGD
In PGD, embryos created through in-vitro fertilization are tested for chromosomal abnormalities prior to replacement in a woman’s uterus. This process allows the reproductive endocrinologist to select only chromosomally healthy embryos for replacement with the goal of increasing the chance of successful implantation, reducing spontaneous abortion, reducing the chance for a fetus to have a chromosomal abnormality and in some cases improving delivery rates for assisted reproduction.

Chromosome abnormalities are the primary cause of miscarriage and more than 50%. This percentage increases with maternal age, and studies have shown that 82% of embryos from woman 40 years and older will be chromosomally abnormal.

About Reprogenetics
Reprogenetics is a private genetics laboratory specializing in Preimplantation Genetic Diagnosis (PGD). Dr. Santiago Munné and Dr. Jacques Cohen founded Reprogenetics in the year 2000 after extensive experience in PGD and IVF. Reprogenetics offers a comprehensive and personalized service to its referring IVF centers and their patients. Genetic counselors are intricately involved in the process and interact routinely with the patients pursuing all PGD tests. 

MELVILLE, NY–(Marketwire – August 3, 2010) –  FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, announced the purchase of an UPRIGHT® Multi-Position™ MRI by Medserena, of Germany. It is the fourth purchase by Medserena. The Other UPRIGHT® MRI scanners in Germany owned by Medserena are located in Cologne, Hanover and Munich.

Matthias Schulz, CEO of Medserena, said, “The first three UPRIGHT® MRI centers have had great success. With physicians all over Germany asking about this technology, it has become imperative for us to expand and install a fourth UPRIGHT® scanner. This is in spite of an intensely active MRI market in Germany, where there are already many conventional lie-down MRI’s installed. The large number of requests coming from our physicians in Germany,” Mr. Schulz said, “are arising because of the special medical need for FONAR’s unique technology.” 

“The German people have a long history in science and technology innovation,” Mr. Schulz reported, “so we tend to recognize the potential of any new technology quickly. We have been very successful in Germany with the FONAR UPRIGHT® Multi-Position™ MRI and its power for scanning patients in multiple upright and recumbent positions because our physicians have quickly appreciated the benefits of this new technology and want their patients to have access to those benefits as soon as possible. With 50% of MRI’s being of the spine, it is self-evident that to make a satisfactory imaging diagnosis of the spine, the spine needs to be supporting its normal weight load which the conventional lie-down MRI does not permit. In addition, the FONAR UPRIGHT® is able to avoid anesthesia for the imaging of young children in many cases, diagnose the fallen cerebellar tonsils (CTE, cerebellar tonsillar ectopia) that occur from whiplash injuries and diagnose scoliosis in young women without the x-rays that give rise to an increased incidence of breast cancer in scoliosis patients.”

Mr. Schulz continued, “The FONAR UPRIGHT® Multi-Position™ MRI is a most unique MRI scanner. We firmly believe that it will become a standard for MRI diagnostics in Europe, especially in evaluating the spine. No other medical technology can put together in one scanner the ability to achieve detailed images of the patient in any and all of the positions that can give rise to his pain. Our basic marketing strategy is to educate the medical community about the unique diagnostic capabilities of the FONAR unit.”

Mr. Schulz commented, “Automobile whiplash injuries are just as much a problem in Germany as they are in any other industrialized nation. It was with great pleasure that we learned of the July 2010 article in “Brain Injury,” that will now make it possible for physicians to visualize these injuries so that the most expedient medical treatment can be provided. This is a huge advantage for the FONAR UPRIGHT® Multi-Position™ MRI when it competes with other MRI scanners.”

“The July 2010 scientific study in “Brain Injury” is a big study,” Mr. Schulz said. “1200 neck pain patients were scanned by MRI. They were divided into 4 groups, consisting of 2 control neck pain groups that did not experience whiplash trauma and 2 neck pain groups that did. The radiologists who read the study images were blinded as to which images were the patient images and which were the control images. The patients were examined in both the upright and recumbent positions. The recumbent MRI images were obtained in a conventional lie-down MRI and the upright images were obtained in the FONAR UPRIGHT® Multi-Position™ MRI. As a result of this study the fallen cerebellar tonsils of a whiplash injury patient can now be reliably visualized by using the FONAR UPRIGHT® Multi-Position™ MRI. From our point of view, here in Germany, the newly published 1200 patient study in “Brain Injury” sets a “new standard of care” for whiplash injury patients.

The sale of the UPRIGHT® MRI was facilitated by Tecserena, GmbH, which was established as a distributor for FONAR’s MRI products in Europe. For additional information about Tecserena, visit www.tecserena.com, or call +49 221 340 289 0.

For FONAR investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™, True Flow™, The Proof is in the Picture™, Spondylography™ Spondylometry™ and Upright Radiology™ are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

NEW YORK, NY–(Marketwire – August 3, 2010) – Allied Healthcare International Inc. (NASDAQ: AHCI) (AIM: AHI), a leading provider of flexible healthcare staffing
services in the United Kingdom, today issued financial results for its
fiscal 2010 third quarter ended June 30, 2010.

To provide investors with a better understanding of the Company’s
performance and because of fluctuations in foreign exchange rates, Allied
is discussing its revenue, gross profit, selling, general & administrative
(SG&A) expenses and operating income at constant exchange rates, which are
calculated using the comparable prior period weighted average exchange
rates. In addition, as the Company’s revenue and gross profit are
generated in the United Kingdom, an analysis, which is contained in the
Historical Revenue and Gross Profit table at the end of this press release,
is included of the last eleven quarters’ revenue and gross profit in pounds
sterling to enable investors to fully understand the underlying trends over
these periods without the effects of currency exchange rates.

Fiscal Third Quarter Results

                                    Three Months Ended
                                         June 30,
                                 ------------------------
                                                      %
                                   2010      2009   Change
                                 --------  -------- -----
                                         Revenue
                                 ------------------------

Homecare                         $ 59,270  $ 52,801  12.3%
Nursing Homes                       4,237     5,774 -26.6%
Hospitals                           4,551     4,528   0.5%
                                 --------  -------- -----
Total, at constant exchange
 rates                             68,058    63,103   7.9%
Effect of foreign exchange         (2,310)        -  -3.7%
                                 --------  -------- -----
Total, as reported               $ 65,748  $ 63,103   4.2%
                                 ========  ======== =====


                                        Three Months Ended June 30,
                                 -----------------------------------------
                                                                       %
                                   2010       %       2009     %     Change
                                 --------  -------  -------- ------  -----
                                               Gross Profit
                                 -----------------------------------------

Homecare                         $ 18,023     30.4% $ 16,272   30.8%  10.8%
Nursing Homes                       1,368     32.3%    1,843   31.9% -25.8%
Hospitals                           1,078     23.7%    1,058   23.4%   2.0%
                                 --------           --------         -----
Total, at constant exchange
 rates                             20,469     30.1%   19,173   30.4%   6.8%
Effect of foreign exchange           (701)                 -          -3.7%
                                 --------           --------         -----
Total, as reported               $ 19,768           $ 19,173           3.1%
                                 --------           --------         -----


                                                    SG&A
                                 -----------------------------------------
SG&A, at constant exchange rates
 & excluding acquisition costs   $ 17,114           $ 16,276           5.1%
Acquisition costs, at constant
 exchange rates                       595                  -           3.7%
                                 --------           --------         -----
SG&A, at constant exchange rates   17,709             16,276           8.8%
Effect of foreign exchange           (533)                 -          -3.3%
                                 --------           --------         -----
Total SG&A, as reported          $ 17,176           $ 16,276           5.5%
                                 --------           --------         -----


                                              Operating Income
                                 -----------------------------------------
Operating Income, at constant
 exchange rates & excluding
 acquisition costs               $  3,355           $  2,897          15.8%
Acquisition costs, at constant
 exchange rates                      (595)                 -         -20.5%
                                 --------           --------         -----
Operating Income, at constant
 exchange rates                     2,760              2,897          -4.7%
Effect of foreign exchange           (168)                 -          -5.8%
                                 --------           --------         -----
Operating Income, as reported    $  2,592           $  2,897         -10.5%
                                 ========           ========         =====


                                     Net income attributable to Allied
                                 -----------------------------------------
                                      Basic and            Basic and
                                     Diluted EPS          Diluted EPS
                                 -----------------------------------------
Net income attributable to
 Allied, excluding acquisition
 costs                           $ 2,270     $  0.05    $ 2,388    $  0.05
Acquisition costs                   (610)   -$  0.01          -          -
                                 -------     -------    -------    -------
Net income attributable to
 Allied                          $ 1,660     $  0.04    $ 2,388    $  0.05
                                 =======     =======    =======    =======

For the third quarter of fiscal 2010, total revenue increased 7.9%, to
$68.0 million, compared with $63.1 million reported during the same period
in fiscal 2009. Allied’s Homecare revenue grew 12.3% to $59.3 million. The
acquisition completed in this quarter contributed 4.0%, or $2.1 million, to
the increase in Homecare revenues. Nursing Homes revenue declined 26.6% to
$4.2 million and Hospitals revenue increased 0.5% to $4.5 million. After
the unfavorable impact of currency exchange of $2.3 million, revenue
increased 4.2% year over year to the reported $65.7 million.

Total gross profit for the third fiscal quarter increased 6.8% to $20.5
million, from $19.2 million for the comparable quarter in fiscal 2009.
Gross profit as a percentage of revenue was 30.1%, compared with 30.4% for
the comparable prior-year period. Foreign exchange decreased gross profit
by $0.7 million to the reported $19.8 million for the 2010 third fiscal
quarter.

SG&A, excluding acquisition costs, for the third fiscal quarter was $17.1
million (25.1% of revenues), an increase of 5.1%, from $16.3 million (25.8%
of revenues) reported last year. The Company also incurred acquisition
costs of $0.6 million. Foreign exchange decreased costs by $0.5 million to
the reported $17.2 million for the 2010 third fiscal quarter.

Operating income, before acquisition costs, for the third quarter of fiscal
2010 increased by 15.8% to $3.4 million from $2.9 million a year ago.
Acquisition costs decreased operating income by $0.6 million. Foreign
exchange decreased operating income by $0.2 million to the reported $2.6
million for the 2010 third fiscal quarter.

Income attributable to Allied, excluding acquisition costs, for the third
quarter of fiscal 2010 was $2.3 million, or $0.05 per diluted share. Net
income attributable to Allied for the third quarter of fiscal 2010 was $1.7
million, or $0.04 per diluted share, compared with $2.4 million, $0.05 per
diluted share, reported during the 2009 third fiscal quarter.

Fiscal Nine Months Results

                                 Nine Months Ended June 30,
                                 --------------------------
                                                       %
                                   2010      2009    Change
                                 --------- --------- ------
                                          Revenue
                                 --------------------------

Homecare                         $ 167,474 $ 145,497  15.1%
Nursing Homes                       13,471    19,295 -30.2%
Hospitals                           14,451    15,173  -4.8%
                                 --------- --------- ------
Total, at constant exchange
 rates                             195,396   179,965   8.6%
Effect of foreign exchange           5,266         -   2.9%
                                 --------- --------- ------
Total, as reported               $ 200,662 $ 179,965  11.5%
                                 ========= ========= ======


                                         Nine Months Ended June 30,
                                 -----------------------------------------
                                                                       %
                                   2010       %       2009     %    Change
                                 --------  -------  -------- ------  -----
                                               Gross Profit
                                 -----------------------------------------

Homecare                         $ 51,380     30.7% $ 45,283   31.1%  13.5%
Nursing Homes                       4,330     32.1%    6,027   31.2% -28.2%
Hospitals                           3,292     22.8%    3,842   25.3% -14.3%
                                 --------           --------         -----
Total, at constant exchange
 rates                             59,002     30.2%   55,152   30.6%   7.0%
Effect of foreign exchange          1,591                  -           2.9%
                                 --------           --------         -----
Total, as reported               $ 60,593           $ 55,152           9.9%
                                 --------           --------         -----


                                                    SG&A
                                 -----------------------------------------
SG&A, at constant exchange rates
 & excluding acquisition costs   $ 48,743           $ 46,224           5.4%
Acquisition costs, at constant
 exchange rates                       595                  -           1.3%
                                 --------           --------         -----
SG&A, at constant exchange rates   49,338             46,224           6.7%
Effect of foreign exchange          1,264                  -           2.8%
                                 --------           --------         -----
Total SG&A, as reported          $ 50,602           $ 46,224           9.5%
                                 --------           --------         -----


                                                Operating Income
                                 -----------------------------------------
Operating Income, at constant
 exchange rates & excluding
 acquisition costs               $ 10,259           $  8,928          14.9%
Acquisition costs, at constant
 exchange rates                      (595)                 -          -6.7%
                                 --------           --------         -----
Operating Income, at constant
 exchange rates                     9,664              8,928           8.2%
Effect of foreign exchange            327                  -           3.6%
                                 --------           --------         -----
Operating Income, as reported    $  9,991           $  8,928          11.9%
                                 ========           ========         =====


                                     Net income attributable to Allied
                                 -----------------------------------------
                                      Basic and            Basic and
                                     Diluted EPS          Diluted EPS
                                 -----------------------------------------
Income from continuing
 operations attributable to
 Allied, excluding acquisition
 costs                           $ 7,766     $  0.17    $ 6,999    $  0.15
Acquisition costs                   (610)   -$  0.01          -          -
                                 -------     -------    -------    -------
Net income attributable to
 Allied                          $ 7,156     $  0.16    $ 6,999    $  0.15
                                 =======     =======    =======    =======

For the nine months of fiscal 2010 total revenue increased 8.6%, to $195.4
million, compared with $180.0 million for the same period in fiscal 2009.
Allied’s Homecare revenue grew 15.1% to $167.5 million. The acquisition
completed in the third quarter of fiscal 2010 contributed 1.4%, or $2.1
million, to the increase in Homecare revenues. Nursing Homes revenue
declined 30.2% to $13.5 million and Hospitals revenue declined 4.8% to
$14.4 million. After the favorable impact of currency exchange of $5.3
million, revenue increased 11.5% year over year to the reported $200.7
million for the fiscal 2010 nine-month period.

Total gross profit for the nine months of fiscal 2010 increased 7.0% to
$59.0 million, from $55.2 million for the comparable period in fiscal 2009.
Gross profit as a percentage of revenue was 30.2%, compared with 30.6% for
the comparable prior-year period. Foreign exchange increased gross profit
by $1.6 million to the reported $60.6 million for the fiscal 2010
nine-month period.

SG&A, excluding acquisition costs, for the nine months of fiscal 2010 was
$48.7 million (24.9% of revenues), an increase of 5.4%, from $46.2 million
(25.7% of revenues) reported last year. We also incurred acquisition
costs of $0.6 million. Foreign exchange increased costs by $1.3 million to
the reported $50.6 million for the fiscal 2010 nine month period.

Operating income, before acquisition costs, for the nine months of fiscal
2010 increased by 14.9% to $10.3 million from $8.9 million a year ago.
Acquisition costs decreased operating income by $0.6 million. Foreign
exchange increased operating income by $0.3 million to the reported $10.0
million for the fiscal 2010 nine month period.

Income attributable to Allied, excluding acquisition costs, for the nine
months of fiscal 2010 was $7.8 million, or $0.17 per diluted share. Income
attributable to Allied for the nine months of fiscal 2010 was $7.2 million,
or $0.16 per diluted share, compared with $7.0 million, $0.15 per diluted
share, reported during the fiscal 2009 nine month period.

Cash balances as of June 30, 2010 were $37.0 million (£24.5 million) as
compared to $41.6 million (£27.6 million) as of March 31, 2010. The
decrease was primarily due to payments on acquisition and the Company’s
share buy back program.

For the fiscal nine months ended June 30, 2010, depreciation and
amortization was $3.2 million (£2.0 million), capital expenditures were
$2.4 million (£1.6 million). Days Sales Outstanding was 27 days at June 30,
2010 (42 days including unbilled account receivables), and 24 days at June
30, 2009 (46 days including unbilled account receivables).

Management Discussion

Sandy Young, Chief Executive Officer of Allied, commented, “Allied’s
Homecare revenue increased by 12.3% year over year. This is less than
previous growth levels and includes a 4.0% contribution from our newly
acquired Homecare business in Ireland. We are pleased with the transaction
progress and see opportunities to share our knowledge of Continuing Care
and learn from the Irish experience of supported living. We anticipate that
the contribution from our Irish business will exceed £10 million in revenue
and £1.2 million in EBITDA in the coming fiscal year. We believe the low
level of outsourcing in the Republic of Ireland will accelerate as the
government tries to extract the best value for taxpayers.

“There is no doubt that with the new budget year, which commenced in April,
Local Authorities have been controlling their spending. We have not seen
any significant decline so far, but local authority social care only
increased by 5.4%. In contrast, Continuing Care, which is funded by the
National Health Services (NHS) Primary Care Trusts (PCT’s), grew by 18%,
resulting in total growth in our Homecare business of 8.3% before the
benefits of Ireland.

“It has been reported that NHS spending will be protected over the life of
the parliament and we expect new outsourcing opportunities to emerge.
Although there will be a change from NHS Primary Care Trusts (about 150
nationally) to General Practitioner Consortia (about 500 nationally) within
two years, we do not see why that will restrict growth. At present PCT’s
outsource only a proportion of their spending and more care will be joint
commissioned as they try to bridge the gap between Healthcare and Social
Care. We are very well positioned to capitalize on these changes in the
industry.

“We have significant scope to increase our Continuing Care business as only
60 of our 113 total branches provide Continuing Care. Further, only about
12 branches provide the full range of Continuing Care, which includes high
intensity patients. We currently have plans to increase our sales and
marketing expenditures to promote these opportunities. We are also
exploring new service lines and during the quarter we piloted the Rapid
Intervention Service for End-of-life care (RISE) launched by NHS
Oxfordshire in July.

“The service aims to make first contact with a patient within 20 minutes at
times of crisis. The team operates between 8.00 am and 10.00 pm seven days
a week and can offer care and support for a maximum of six days. If
patients require overnight care, then the service will link with Marie
Curie Night Service or Out of Hours services. Furthermore, if ongoing care
is required, the RISE team also works to make sure other services are
involved so care can be continued if necessary.

“While we are positive about health spending, we can see there may be some
slowing in Local Authority spending. However, we believe that the larger
dynamics in this business will continue to have a positive impact.
Firstly, there is the steady increase because of the ageing profile of the
population. Secondly, a number of Local Authorities have not outsourced
care to the private sector. Thirdly, the reduction in the number of
suppliers used by each Authority will favor the larger players.

“Finally, quality is a major driver and we are delighted that we now have
91% of our branches rated by the Government (CQC) as good or excellent. In
the provision of such a sensitive service, quality is paramount.

“In the last month, we have won a 1,000 hours per week contract in Wales,
an 1,100 hour per week extra care scheme in London, and a place on the West
London Alliance which could be significantly more than 1,000 hours per
week.

“So we are still winning business but cannot quantify the effects of
savings in other areas. We are well placed to benefit from volume deals and
some of the smaller providers may find the temporary volume restrictions
hard.

“Overall I would hope that our Homecare business (before the benefit of
Ireland) can continue to grow in the 5% to 10% range rather than the 10% to
15% range previously highlighted. I think the 5% to 10% growth level will
be a feature of the medium term as the Local Authorities and PCT’s adjust,
but thereafter I see no reason why we will not return to the higher levels
of growth, particularly given the reinforced emphasis on outsourcing. There
are already other outsourcing opportunities Allied can initiate.

“Our Nursing Home activities continued to decline and we do not foresee any
immediate change. However, with Hospital Staffing we have posted a small
growth of 1%. We have also started to extract this business from our
Homecare network to allow for more focus. It now reports in to our
Commercial Director.”

Mr. Young concluded, “To support our commitment to providing our customers
with one of the highest levels of quality care in our industry and to
enhancing our leadership, Professor Raymond J. Playford has been appointed
to the new post of Medical Advisor to our Board. Professor Playford has
more than 25 years of experience in the medical field, specialising in
clinical research, and we look forward to benefiting from his profound
health care expertise, particularly in this environment.”

Dr. Jeff Peris, Chairman of Allied, commented, “Looking forward, we will
focus on executing our business strategy and building value for our
shareholders through organic growth, new service opportunities, strategic
acquisitions, as well as through our share buyback program. As of July 30,
2010 we had repurchased 1.1 million shares, or approximately $2.8 million,
of our stock under the $10 million stock repurchase program announced in
May 2010.”

Conference Call Information: August 3, 2010 at 10:00 AM Eastern Time /
3:00 PM UK Time

Allied will host a call and webcast today at 10:00 AM Eastern Time / 3:00
PM UK Time, to discuss its financial results. To join the call, please dial
(877) 407-8031 for domestic participants and (201) 689-8031 for
international participants. Participants may also access a live webcast of
the conference call through the “Investors” section of Allied Healthcare’s
Website: www.alliedhealthcare.com. A telephone replay will be available
until August 31st following the call by dialing (877) 660-6853 for domestic
participants and (201) 612-7415 for international participants. When
prompted, please enter account number 286 and conference ID number 353906.
A webcast replay will also be available and archived on the Company’s
website for ninety days.

Reconciliation of GAAP and Non-GAAP Data

In addition to disclosing results of operations that are determined in
accordance with generally accepted accounting principles (“GAAP”), this
press release also discloses non-GAAP results of operations that exclude or
include certain charges. These non-GAAP measures adjust for foreign
exchange effects and acquisition costs. Management believes that the
presentation of these non-GAAP measures provides useful information to
investors regarding the Company’s results of operations, as these non-GAAP
measures allow investors to better evaluate ongoing business performance.
Investors should consider non-GAAP measures in addition to, and not as a
substitute for, financial measures prepared in accordance with GAAP. A
reconciliation of the non-GAAP measures disclosed in this press release
with the most comparable GAAP measures are included in the financial tables
included in this press release.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.

Allied Healthcare International Inc. is a leading provider of flexible
healthcare staffing services in the United Kingdom. Allied operates a
community-based network of approximately 115 branches with the capacity to
provide carers (known as home health aides in the U.S.), nurses, and
specialized medical personnel to locations covering approximately 90% of
the U.K. population. Allied meets the needs of private patients, community
care, nursing and care homes, and hospitals. For more news and information
please visit: www.alliedhealthcare.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release may be forward-looking
statements. These forward-looking statements are based on current
expectations and projections about future events. Actual results could
differ materially from those discussed in, or implied by, these
forward-looking statements. Factors that could cause actual results to
differ from those implied by the forward-looking statements include:
general economic and market conditions; the effect of the change in the
U.K. government and the impact of proposed changes in recent policy making
related to health and social care that may reduce revenue and
profitability; Allied’s ability to continue to recruit and retain flexible
healthcare staff; Allied’s ability to enter into contracts with local
government social services departments, NHS Trusts, hospitals, other
healthcare facility clients and private clients on terms attractive to
Allied; the general level of demand and spending for healthcare and social
care; dependence on the proper functioning of Allied’s information systems;
the effect of existing or future government regulation of the healthcare
and social care industry, and Allied’s ability to comply with these
regulations; the impact of medical malpractice and other claims asserted
against Allied; the effect of regulatory change that may apply to Allied
and that may increase costs and reduce revenues and profitability; Allied’s
ability to use net operating loss carry forwards to offset net income; the
effect that fluctuations in foreign currency exchange rates may have on our
dollar-denominated results of operations; and the impairment of goodwill,
of which Allied has a substantial amount on the balance sheet, may have the
effect of decreasing earnings or increasing losses. Other factors that
could cause actual results to differ from those implied by the
forward-looking statements in this press release include those described in
Allied’s most recently filed SEC documents, such as its most recent annual
report on Form 10-K, all quarterly reports on Form 10-Q and any current
reports on Form 8-K filed since the date of the last Form 10-K. Allied
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or
otherwise.

ALLIED HEALTHCARE INTERNATIONAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

                                  Three Months Ended    Nine Months Ended
                                --------------------- --------------------
                                 June 30,   June 30,   June 30,   June 30,
                                   2010       2009       2010       2009
                                ---------  ---------- ---------  ---------
Revenues:
  Net patient services          $  65,748  $   63,103 $ 200,662  $ 179,965
                                ---------  ---------- ---------  ---------

Cost of revenues:
  Patient services                 45,980      43,930   140,069    124,813
                                ---------  ---------- ---------  ---------

     Gross profit                  19,768      19,173    60,593     55,152

Selling, general and
 administrative expenses           17,176      16,276    50,602     46,224
                                ---------  ---------- ---------  ---------

     Operating income               2,592       2,897     9,991      8,928

Interest income                        84          76       275        453
Interest expense                      (10)          -       (10)       (12)
Foreign exchange (loss) income        (46)        307      (259)       (60)
                                ---------  ---------- ---------  ---------

     Income before income
      taxes and discontinued
      operations                    2,620       3,280     9,997      9,309

Provision for income taxes            903         892     2,784      2,310
                                ---------  ---------- ---------  ---------

     Income from continuing
      operations                    1,717       2,388     7,213      6,999
                                ---------  ---------- ---------  ---------

Discontinued operations:
Income from discontinued
 operations, net of taxes               -           -         -        367
                                ---------  ---------- ---------  ---------

Net income                          1,717       2,388     7,213      7,366

Less: Net income attributable
 to noncontrolling interest           (57)          -       (57)         -
                                ---------  ---------- ---------  ---------

Net income attributable to
 Allied Healthcare
 International Inc.             $   1,660  $    2,388 $   7,156  $   7,366
                                =========  ========== =========  =========

Amounts attributable to Allied
 Healthcare International Inc.:
     Income from continuing
      operations, net of tax    $   1,660  $    2,388 $   7,156  $   6,999
     Discontinued operations,
      net of tax                        -           -         -        367
                                ---------  ---------- ---------  ---------
     Net income                 $   1,660  $    2,388 $   7,156  $   7,366
                                =========  ========== =========  =========

Earnings per share - basic and
 diluted attributable to Allied
 Healthcare International Inc.
 common shareholders
     Income from continuing
      operations                $    0.04  $     0.05 $    0.16  $    0.15
     Discontinued operations            -           -         -       0.01
                                ---------  ---------- ---------  ---------
Net income attributable to
 Allied Healthcare
 International Inc.
 common shareholders            $    0.04  $     0.05 $    0.16  $    0.16
                                =========  ========== =========  =========

Weighted average number of
 common shares outstanding:
     Basic                         45,045      44,986    45,102     44,986
                                =========  ========== =========  =========
     Diluted                       45,269      44,998    45,363     44,990
                                =========  ========== =========  =========





ALLIED HEALTHCARE INTERNATIONAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

                                                    June 30,  September 30,
                                                      2010         2009
                                                  (Unaudited)
                                                  -----------  -----------
ASSETS

Current assets:
  Cash and cash equivalents                       $    36,954  $    35,273
  Accounts receivable, less allowance for
   doubtful accounts of $694 and $839,
   respectively                                        19,584       19,594
  Unbilled accounts receivable                         10,970       11,572
  Deferred income taxes                                   403          389
  Prepaid expenses and other assets                     1,501        1,188
                                                  -----------  -----------
         Total current assets                          69,412       68,016

Property and equipment, net                             9,303        7,756
Goodwill                                               98,114       95,649
Other intangible assets, net                            3,699        1,646
                                                  -----------  -----------
         Total assets                             $   180,528  $   173,067
                                                  ===========  ===========

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Accounts payable                                $     1,099  $     1,186
  Current maturities of debt and capital leases           567            -
  Accrued expenses, inclusive of payroll and
   related expenses                                    24,866       24,304
  Taxes payable                                           970          201
                                                  -----------  -----------
         Total current liabilities                     27,502       25,691

Long-term debt and capital leases,
 net of current maturities                                394            -
Deferred income taxes                                   1,425          103
Other long-term liabilities                               294            -
                                                  -----------  -----------
         Total liabilities                             29,615       25,794
                                                  -----------  -----------

Commitments and contingencies

                                                  -----------  -----------
Noncontrolling interest                                 4,028            -
                                                  -----------  -----------

Shareholders' equity:
  Preferred stock, $.01 par value; authorized
   10,000 shares, issued and outstanding - none             -            -
  Common stock, $.01 par value; authorized 80,000
   shares, issued 45,721 and 45,571 shares,
   respectively                                           457          456
  Additional paid-in capital                          242,312      241,555
  Accumulated other comprehensive loss                (21,403)     (14,418)
  Accumulated deficit                                 (70,870)     (78,026)
                                                  -----------  -----------
                                                      150,496      149,567
  Less cost of treasury stock (1,089 and 585
   shares, respectively)                               (3,611)      (2,294)
                                                  -----------  -----------
         Total shareholders' equity                   146,885      147,273
                                                  -----------  -----------
         Total liabilities and shareholders'
          equity                                  $   180,528  $   173,067
                                                  ===========  ===========





ALLIED HEALTHCARE INTERNATIONAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

                                                        Nine Months Ended
                                                        June 30,  June 30,
                                                          2010      2009
                                                        --------  --------
Cash flows from operating activities:
  Net income                                            $  7,213  $  7,366
  Adjustments to reconcile net income to net
   cash provided by operating activities:
     Income from discontinued operations                       -      (367)
     Depreciation and amortization                         2,242     1,880
     Amortization of intangible assets                       952       921
     Foreign exchange gain                                    (2)     (221)
     (Decrease) increase in provision for
      allowance for doubtful accounts                        (24)      100
     (Gain) loss on sale of fixed assets                      (2)       11
     Stock based compensation                                471       366
     Deferred income taxes                                   102      (246)
  Changes in operating assets and liabilities,
   excluding the effect of businesses acquired and
   sold:
     Increase in accounts receivable                        (335)     (518)
     Decrease (increase) in prepaid expenses
      and other assets                                       671    (1,137)
     Increase in accounts payable and other
      liabilities                                          1,693     2,875
                                                        --------  --------

        Net cash provided by continuing
         operations                                       12,981    11,030
                                                        --------  --------

Cash flows from investing activities:
  Capital expenditures                                    (2,428)   (2,152)
  Proceeds from sale of business                               -       114
  Proceeds from sale of property and equipment                62         1
  Acquisition of controlling interest,
   net of cash acquired                                   (5,812)        -
  Payments on acquisitions payable                             -      (171)
                                                        --------  --------

        Net cash used in investing activities             (8,178)   (2,208)
                                                        --------  --------

Cash flows from financing activities:
  Stock options exercised                                    288         -
  Borrowings under invoice discounting facility, net         248         -
  Repayments of debt and capital lease obligations          (121)        -
  Treasury shares acquired                                (1,317)        -
                                                        --------  --------

        Net cash used in financing activities               (902)        -
                                                        --------  --------

Effect of exchange rate on cash                           (2,220)   (1,361)
                                                        --------  --------

Increase in cash                                           1,681     7,461

Cash and cash equivalents, beginning of period            35,273    26,199
                                                        --------  --------

Cash and cash equivalents, end of period                $ 36,954  $ 33,660
                                                        ========  ========

Supplemental cash flow information:
  Cash paid for interest                                $     10  $    300
                                                        ========  ========

  Cash paid for income taxes, net                       $  1,025  $    137
                                                        ========  ========

Supplemental disclosure of non-cash investing
 and financing activities:
  Capital expenditures included in accrued expenses
   and other long-term liabilities                      $    609  $      -
                                                        ========  ========

  Details of business acquired in purchase
   transactions:
     Fair value of assets acquired                      $ 12,430
                                                        ========

     Liabilities assumed or incurred                    $  2,694
                                                        ========

     Noncontrolling interest                            $  3,888
                                                        ========

     Cash paid for acquisitions                         $  5,848
     Cash acquired                                            36
                                                        --------

     Net cash paid for acquisitions                     $  5,812
                                                        ========





ALLIED HEALTHCARE INTERNATIONAL INC.
HISTORICAL REVENUE AND GROSS PROFIT
(In thousands, except foreign exchange rate)
(Unaudited)

                                             Revenue
                                ---------- ---------- ----------
                                    Q3         Q2         Q1
                                  2010       2010       2010
                                ---------- ---------- ----------

Homecare                        GBP 38,323 GBP 35,860 GBP 35,903
Nursing Homes                        2,731      2,864      3,261
Hospitals                            2,933      3,235      3,330
                                ---------- ---------- ----------
Total                           GBP 43,987 GBP 41,959 GBP 42,494
Foreign Exchange rate                 1.49       1.56       1.63
                                ---------- ---------- ----------
                                $   65,748 $   65,530 $   69,384
                                ========== ========== ==========


                                                 Revenue
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2009       2009       2009       2009
                                ---------- ---------- ---------- ----------

Homecare                        GBP 35,763 GBP 34,162 GBP 30,858 GBP 30,620
Nursing Homes                        3,986      3,716      4,159      4,808
Hospitals                            2,956      2,914      3,448      3,612
                                ---------- ---------- ---------- ----------
Total                           GBP 42,705 GBP 40,792 GBP 38,465 GBP 39,040
Foreign Exchange rate                 1.64       1.55       1.44       1.58
                                ---------- ---------- ---------- ----------
                                $   69,845 $   63,103 $   55,334 $   61,528
                                ========== ========== ========== ==========


                                                 Revenue
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2008       2008       2008       2008
                                ---------- ---------- ---------- ----------

Homecare                        GBP 30,218 GBP 29,130 GBP 27,561 GBP 27,358
Nursing Homes                        5,140      4,969      5,373      5,730
Hospitals                            4,088      3,926      4,358      3,473
                                ---------- ---------- ---------- ----------
Total                           GBP 39,446 GBP 38,025 GBP 37,292 GBP 36,561
Foreign Exchange rate                 1.90       1.97       1.98       2.05
                                ---------- ---------- ---------- ----------
                                $   74,968 $   75,024 $   73,815 $   74,770
                                ========== ========== ========== ==========



                                          Gross Profit
                                ---------- ---------- ----------
                                    Q3         Q2         Q1
                                  2010       2010       2010
                                ---------- ---------- ----------

Homecare                        GBP 11,651 GBP 11,083 GBP 11,041
Nursing Homes                          882        931      1,033
Hospitals                              696        755        712
                                ---------- ---------- ----------
Total                           GBP 13,229 GBP 12,769 GBP 12,786
Foreign Exchange rate                 1.49       1.56       1.63
                                ---------- ---------- ----------
                                $   19,768 $   19,948 $   20,877
                                ========== ========== ==========


                                               Gross Profit
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2009       2009       2009       2009
                                ---------- ---------- ---------- ----------

Homecare                        GBP 10,951 GBP 10,525  GBP 9,753  GBP 9,487
Nursing Homes                        1,257      1,187      1,298      1,477
Hospitals                              745        679        874        973
                                ---------- ---------- ---------- ----------
Total                           GBP 12,953 GBP 12,391 GBP 11,925 GBP 11,937
Foreign Exchange rate                 1.64       1.55       1.44       1.58
                                ---------- ---------- ---------- ----------
                                $   21,196 $   19,173 $   17,166 $   18,813
                                ========== ========== ========== ==========


                                               Gross Profit
                                ---------- ---------- ---------- ----------
                                    Q4         Q3         Q2         Q1
                                  2008       2008       2008       2008
                                ---------- ---------- ---------- ----------

Homecare                         GBP 9,447  GBP 9,294  GBP 8,476  GBP 8,491
Nursing Homes                        1,554      1,531      1,596      1,706
Hospitals                            1,050        888      1,009        767
                                ---------- ---------- ---------- ----------
Total                           GBP 12,051 GBP 11,713 GBP 11,081 GBP 10,964
Foreign Exchange rate                 1.90       1.97       1.98       2.05
                                ---------- ---------- ---------- ----------
                                $   22,911 $   23,120 $   21,931 $   22,423
                                ========== ========== ========== ==========

JERICHO, NY–(Marketwire – August 3, 2010) – SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces that Preferred Distribution, Inc., the Company’s medical and dental products subsidiary, has signed a Letter of Intent (“LOI”) to acquire the exclusive licensing rights to SoleCare®, an innovative, patent pending, podiatry product.

SoleCare® is a unique new product for the removal of calluses by pedicurists.

The Company expects the continuing negotiations to result in a definitive agreement in the near term.

Dr. Gary Wallach, the inventor of SoleCare®, stated: “I am very excited about the decision to work with SciMeDent on the development and distribution of my SoleCare line of products.”

Dr. Stahl, CEO of TRDX, commented: “We advanced our discussions from a distribution relationship to an exclusive license deal. Having a license makes us more of a partner with Dr. Wallach and the SoleCare® team.”

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

IRVINE, CA–(Marketwire – August 3, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced that it plans to offer 19,300,000 shares of its common stock in an underwritten public offering through an existing shelf registration statement. In connection with the offering, Sun expects to grant the underwriters a 30-day option to purchase up to 2,895,000 additional shares of its common stock to cover any over-allotments, if applicable.

Sun intends to use the net proceeds from this offering to repay a portion of the outstanding term loans under its existing credit facility.

Jefferies & Company, Inc., Credit Suisse Securities (USA) LLC and J.P. Morgan Securities Inc. are the joint book-running managers for this offering.

This press release does not constitute an offer to sell or a solicitation of any offer to buy the shares of Sun’s common stock described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering may be made only by means of the prospectus supplement and the related prospectus relating to the proposed offering, copies of which may be obtained, when available, by written request to Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12^th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010 or by telephone at (800) 221-1037.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary. 

Forward-Looking Statements 

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by the Company with the Securities and Exchange Commission and include our ability to successfully complete the offering on terms and conditions satisfactory to us, as well as other risks and uncertainties, including those detailed from time to time in our Securities and Exchange Commission filings. More information on factors that could affect our business and financial results are included in our public filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control. We caution investors that any forward-looking statements made by Sun are not guarantees of future performance. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

NASHVILLE, TN–(Marketwire – August 2, 2010) – Vanguard Health Systems, a Nashville-based healthcare company, today announced that affiliates of Vanguard have acquired two acute care hospitals and associated outpatient facilities in Illinois from Resurrection Health Care. Located in the western suburbs of Chicago, the hospitals are 234-bed West Suburban Medical Center in Oak Park, Illinois and 225-bed Westlake Hospital in Melrose Park, Illinois. 

This transaction supports Vanguard’s strategy of developing urban-based health care delivery networks by expanding its presence in the western suburbs where the company has served the community through its ownership of MacNeal Hospital since 2000. By achieving scale in urban markets, Vanguard is able to further its vision of providing health and health care to the communities it serves.

“We are committed to the Chicago-area as evidenced by our decade long involvement with Berwyn and neighboring communities through our ownership of MacNeal Hospital and want to expand our service to West Suburban Medical Center and Westlake Hospital,” said Charlie Martin, Chairman and CEO of Vanguard. “We look forward to bringing the necessary capital and strategic expertise needed to sustain and build upon the great clinical care provided by the employees, nurses and physicians at these two organizations.”

About Vanguard
 Vanguard owns and operates 17 acute care hospitals with 4,594 licensed beds and complementary facilities and services in Chicago, Illinois; Phoenix, Arizona; San Antonio, Texas; and Massachusetts. Vanguard’s total revenues for its last fiscal year ended June 30, 2009, were approximately $3.2 billion. Vanguard’s strategy is to develop locally branded, comprehensive healthcare delivery networks in urban markets. Vanguard will pursue acquisitions where there are opportunities to partner with leading delivery systems in new urban markets. Upon acquiring a facility or network of facilities, Vanguard implements strategic and operational improvement initiatives including expanding services, strengthening relationships with physicians and managed care organizations, recruiting new physicians and upgrading information systems and other capital equipment. These strategies improve quality and network coverage in a cost effective and accessible manner for the communities we serve.

This press release contains forward-looking statements within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby. These forward-looking statements include all statements that are not historical statements of fact and those statements regarding Vanguard’s intent, belief or expectations. Do not rely on any forward-looking statements as such statements are subject to numerous factors, risks and uncertainties that could cause Vanguard’s actual outcomes, results, performance or achievements to be materially different from those projected. These factors, risks and uncertainties include, among others, Vanguard’s high degree of leverage and interest rate risk; Vanguard’s ability to incur substantially more debt; operating and financial restrictions in Vanguard’s debt agreements; Vanguard’s ability to generate cash to service its debt; potential liability related to disclosures of relationships between physicians and Vanguard’s hospitals; Vanguard’s ability to grow its business and successfully implement its business strategies; Vanguard’s ability to successfully integrate any future acquisitions; the potential that acquisitions could be costly, unsuccessful or subject Vanguard to unexpected liabilities; post-payment claims reviews by governmental agencies that could result in additional costs to Vanguard; conflicts of interest that may arise as a result of Vanguard’s control by a small number of stockholders; the highly competitive nature of the healthcare business; governmental regulation of the industry including Medicare and Medicaid reimbursement levels; changes in Federal, state or local regulation affecting the healthcare industry; the potential impact to us of the significant Federal healthcare reform enacted by Congress in March 2010 and potential additional Federal or state healthcare reform; pressures to contain costs by managed care organizations and other insurers and Vanguard’s ability to negotiate acceptable terms with these third party payers; the ability to attract and retain qualified management and personnel, including physicians and nurses; claims and legal actions relating to professional liabilities or other matters; the impacts of weakened economic conditions and volatile capital markets on Vanguard’s results of operations, financial position and cash flows; Vanguard’s failure to adequately enhance its facilities with technologically advanced equipment could adversely affect its revenues and market position; Vanguard’s exposure to the increased amounts of and collection risks associated with uninsured accounts and the co-pay and deductible portions of insured accounts; Vanguard’s ability to maintain or increase patient membership and control costs of its managed healthcare plans; the geographic concentration of Vanguard’s operations; the technological and pharmaceutical improvements that increase the cost of providing healthcare services or reduce the demand for such services; the timeliness of reimbursement payments received under government programs; the potential adverse impact of known and unknown government investigations; and those factors, risks and uncertainties detailed in Vanguard’s filings from time to time with the Securities and Exchange Commission, including, among others, Vanguard’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.

Although Vanguard believes that the assumptions underlying the forward-looking statements contained in this press release are reasonable, any of these assumptions could prove to be inaccurate, and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, you should not regard the inclusion of such information as a representation by Vanguard that its objectives and plans anticipated by the forward-looking statements will occur or be achieved, or if any of them do, what impact they will have on Vanguard’s results of operations and financial condition. Vanguard undertakes no obligation to publicly release any revisions to any forward-looking statements contained herein to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

LEXINGTON, MA–(Marketwire – August 2, 2010) –   Imprivata®, Inc., the company that simplifies and secures user access, today announced the general availability of Imprivata OneSign 4.5. With breakthrough features such as OneSign Secure Walk-Away, and capabilities such as strong authentication for Citrix and RDP sessions, enhanced support for virtualized desktops and FIPS 140-2 compliance, the new release solves the critical workflow and security challenges organizations face by strengthening user authentication, streamlining application access and simplifying compliance reporting.

“Imprivata OneSign has grown to the point that our users see it as another service we offer to make their lives easier,” said Jack Thompson, senior customer support tech, Southwest Washington Medical Center. “When your product is able to provide security and productivity at the same time, you’re doing something right.” 

IMPROVED END-USER WORKFLOW

OneSign 4.5 delivers enhancements to many of the existing features that have made the product the leader in its category, and introduces new features that change the way organizations think about secure access to applications.

• Automatic Desktop Locking via OneSign Secure Walk-Away uses intelligent computer vision technology with active presence detection to secure unattended desktops without changing end-user behavior. This removes the security burden from the user and reduces the time and frustration associated with logging on/off of applications. Secure Walk-Away is particularly useful in healthcare, where clinicians who constantly log on/off of electronic medical records (EMR) and other applications are now free to focus on improving patient care rather than IT security. 
• One-touch Roaming and Location Awareness enables desktops to follow users throughout the organization, making the electronic data they need available to them wherever they are with just the touch of a finger or the tap of a proximity card. Imprivata OneSign can be configured to be fully location aware, meaning application, default printer and user privileges are configured dynamically based on the particular workstation being accessed by the user. Imprivata OneSign complements desktop virtualization from VMware View and Oracle Sun Ray, by adding the capabilities to enable secure roaming including strong authentication, single sign-on (SSO), session management and location-aware desktop personalization and customization. 

INCREASED IT SECURITY

• Transparent Screen Locking secures a computer desktop from unauthorized access while at the same time maintaining the desktop/applications’ visibility for monitoring purposes. This feature is critical to healthcare, where particular sessions must be locked, while patient status remains visible to care givers. 
• Enhanced Transaction-based Authentication supports additional workflows through OneSign ProveID, Imprivata’s unique feature being used by leading EMR vendors for ePrescribing. 
• Fingerprint Identification Enhancements enable scalability to accommodate the largest organizations.

ENHANCED DELIVERY/PACKAGING OPTIONS

• The OneSign Virtual Appliance is a self contained software implementation of the OneSign server that is functionally equivalent to the hardware appliance. OneSign virtual appliances are formatted using the industry standard Open Virtualization Format (OVF). Heterogeneous enterprises can be deployed with both virtual and hardware OneSign Appliances.
• FIPS 140-2 compliance
• Windows 7 support

“Improving user productivity and securing data are inherently competing goals,” commented Omar Hussain, president and CEO at Imprivata. “As our customers rely increasingly on fast access to digital data to be successful, security and compliance requirements across industries around the world are making access to that data more and more difficult. Imprivata has earned its leadership position by anticipating customer needs and continuing to deliver new and unique technologies that simplify and secure access to corporate data. Imprivata OneSign 4.5 is the latest proof that user productivity and IT security do not have to be mutually exclusive.” 

Centrally managed from a single administrative console, Imprivata OneSign secures access across Windows, host-based, Citrix and virtual desktop environments. OneSign empowers organizations to balance the need for stronger security with improved user workflow and productivity. The solution also reduces the time and complexity of complying with regulated access control requirements and password management costs that consume IT help desk resources.

About Imprivata
Imprivata is the leading independent vendor focused on simplifying and securing user access. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers realize substantial IT helpdesk and administration cost savings, while achieving the security standards they demand.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews
Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

KANKAKEE, IL–(Marketwire – August 2, 2010) – Riverside Medical Center’s recent investment in a new state-of-the art Interventional Radiology (IR) system, greatly expands the advanced services it can now offer the Kankakee Illinois healthcare community. Riverside saw an opportunity to re-engineer the patient experience and improve workflow around the Kankakee County hospital and they jumped at the chance.

Riverside’s IR room underwent a complete remodel and expansion. The new room, which cost nearly $2 million, features positive air pressure making it operating room compatible. The room now uses Toshiba’s Infinix-i-x-ray system. This new imaging system has greatly impacted the quality of care and safety for the patient that this south Chicago healthcare giant can provide. Being able to control the amount of radiation administered is extremely important to the patient, radiologists and staff. This new system equips the physicians and radiologists with a comprehensive dose management package that allows for greater control, superior precision and less exposure to radiation. 

The equipment, which was once controlled in a separate room, can now be completely controlled in one area, allowing the staff to remain with the patient for added safety. In addition, Riverside Medical Center has paired the x-ray system with Toshiba’s 12″x12″ mid-sized flat panel detector. Together, they offer a wider field-of-view and provide increased visualization and optimal access, helping radiologists more quickly and accurately diagnose and treat patients.

Radiologists are now also able to view the patient’s images on a live feed and can immediately pull up a patient’s previous scans and display them on the monitors for comparison. Doctors now have immediate access to angiograms, physiological monitoring, CT and MRI scans, and many other imaging or patient specific data that can be displayed throughout the entire procedure. Clearer, sharper images and enhanced system utilization are all important features of today’s interventional radiology room.

Previously, a patient was literally moved in many different directions in order to perform the procedure. With Riverside’s advanced new technology, the unit moves to the patient. When combining the five-axis positioner with the tilting and cradling features of the table, physicians are able to obtain optimal angles for interventional procedures without re-positioning the patient. With these modern updates, Riverside is caring for patients in new and exciting ways.

To learn more about the quality services offered by Riverside Medical Center, visit www.RiversideMC.net or call (815) 933-1671.

Click here to see all recent news from this company

MOUNTAIN VIEW, CA–(Marketwire – August 2, 2010) –  NCP engineering, Inc. today announced that American Hospice has selected the NCP Secure Enterprise Solution to protect patient data reported by its 180 home healthcare employees. Staff now use NCP’s remote access software to connect their Windows Mobile-based devices to American Hospice’s network, and access and update patient information in real time from anywhere, securely and in full compliance with HIPAA regulations.

NCP’s technology also allows American Hospice and its home healthcare staff to maximize efficiency and improve patient care while on the road. Previously, employees’ recordkeeping was a manual, paper-based system, which often took a week or more to process. Today, staff can safely check their patients’ medical records and home visit schedules, track their travel mileage and immediately provide patient status updates. The NCP Secure Enterprise Solution secures all of the information on the devices themselves and while in transit to the hospice’s network, a key HIPAA requirement.

Key Facts:

• American Hospice is a national leader in the delivery of hospice services. Its interdisciplinary teams, including physicians, nurses, hospice aides, pharmacists, medical social workers, spiritual care specialists, bereavement counsellors and hospice volunteers, serve several thousand patients every day.

• The NCP Secure Enterprise Solution was rolled out in May 2010, with NCP engineering meeting American Hospice’s five-day deployment deadline — taking only three days.

• 180 home healthcare employees stationed throughout Arizona, Georgia, New Jersey, Oklahoma and Virginia use NCP’s one-click IPsec VPN client to synchronize and securely transmit patient data from their Windows Mobile-based devices to the hospice’s server.

• The NCP Secure Enterprise Management System provides American Hospice’s IT staff with a single point of administration for the hospice management company’s entire VPN network, as well as full NAC management. Network administrators can easily control user and device provisioning, and distribute plug-in updates and configuration settings.

Supporting Quotes:

• “Our team tested several VPN solutions, but the NCP Secure Enterprise Solution was the only one able to fully meet our remote access needs,” said Fred Cruz, IT director, American Hospice. “We were extremely impressed with the company’s technology and support during the deployment phase. The stability to ensure a secure communications environment for our healthcare staff has become a cornerstone of our mission to provide the highest quality care to our patients and their families.”

• “American Hospice required a complete, flexible and user-friendly VPN solution for its mobile workforce,” said H. Peter Felgentreff, president and CEO, NCP engineering, Inc. “We are pleased to have fit the bill, and helped the healthcare customer not only rethink its secure remote access but also maximize employee productivity and reduce its operational costs.” 

Resources:

• For more information about American Hospice, please visit www.americanhospice.com.

• For more information about NCP engineering, please visit www.ncp-e.com. Reach the company on its blog, VPN Haus, or on Twitter.

• To learn how NCP engineering enables its customers to rethink remote access with its “Next Generation Network Access Technology”, please visit http://www.ncp-e.com/en/solutions/rethink-remote-access.html.

Tags:
NCP engineering, American Hospice, remote access, VPN, healthcare, HIPAA, security, network, enterprise

About NCP engineering, Inc.
Since its inception in 1986, NCP engineering has delivered innovative software that allows enterprises to rethink their secure remote access, and overcome the complexities of creating, managing and maintaining network access for staff.

NCP’s award-winning product line spans the spectrum of remote access, from IPSec / SSL VPN to endpoint firewalls and network access control (NAC) functions. The company’s products support organizations with complex remote user needs, who want to leverage the latest end-devices to increase staff productivity, reduce network administration and adapt policy changes on-the-fly. Each solution is interoperable with existing third-party software or hardware.

Headquartered in the San Francisco Bay Area, the company serves 30,000-plus customers worldwide throughout the healthcare, financial, education and government markets, as well as many Fortune 500 companies. NCP has established a network of national and regional technology, channel and OEM partners to serve its customers. For more information, visit www.ncp-e.com.

id=”nav_links”>

SPRINGFIELD, OH–(Marketwire – August 2, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has closed on a previously announced agreement to lease five privately held nursing homes in South Georgia that is expected to more than double its revenue.

The five facilities have been leased under a five-year term from the owner, with an extension option for an additional five years. The facilities have on aggregate 615 beds that generate approximately $35 million in annualized revenue.

AdCare’s upfront cost for the transaction was $700,000 in cash, plus legal and accounting closing costs. At closing, the company assumed approximately $1.3 million in negative working capital and purchased for $2 million approximately $5.5 million in existing receivables due to these facilities. In addition, AdCare provided the lessor $1.16 million, comprised of the first month’s lease payment and a security deposit that includes an amount equal to two months lease payment.

With the close of this transaction, AdCare estimates its revenue run-rate will exceed $61 million annually, representing an increase of more than 120% over the company’s 2009 revenues.

“This lease is the first major transaction we closed since we began our acquisition campaign at the end of last year,” said Chris Brogdon, AdCare’s vice chairman and chief acquisitions officer. “We expect these facilities to be very profitable for AdCare, especially as they come under our more capable management and benefit from the economies of scale we bring to the table.”

AdCare also reported it signed an agreement to lease an additional five nursing homes in Georgia that produce annualized revenues of approximately $37 million, which it plans to close on September 30, 2010.

“We are also now moving quickly toward closing the other two acquisitions we announced in the first half of 2010,” noted Brogdon. “As we have outlined in our M&A strategy, we are also continuing to evaluate foreclosures and other poorly run facilities that we can secure at below-market prices, as well as target acquisitions of both profitable and turnaround properties to grow our business.”

Brogdon joined AdCare last September when the company announced a new M&A growth strategy to build upon its strong reputation for operational efficiency and high-quality living environments.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law, which can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “anticipates” or similar expressions. Statements in this announcement that are forward-looking include, but are not limited to, statements that with the closing of this transaction, AdCare estimates its revenue run-rate will exceed $61 million annually, representing an increase of more than 120% over the company’s 2009 revenues; that the leased facilities mentioned in this release will be very profitable for AdCare; that it plans to close the newly announced additional five leases on September 30, 2010; and that the company is moving quickly toward closing the other two acquisitions it announced in the first half of 2010. Such forward-looking statements reflect management’s beliefs and assumptions, and are based on information currently available to management. The forward-looking statements involve known and unknown risks that may make the results, performance or achievements of the company differ materially from those expressed or implied in such statements. Such factors are also identified in the public filings made by the company with the U.S. Securities and Exchange Commission, and they include, but are not limited to, the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs, and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

CARMEL, IN–(Marketwire – August 2, 2010) –  Clinical Architecture today announced that UMass Memorial Health Care, the largest healthcare system in Central and Western Massachusetts, has selected Clinical Architecture’s Symedical™ interoperability solution. UMass Memorial is using Symedical™ to re-code patient data from various locations and terminologies into a central data repository using a single terminology set. “Merging patient data from disparate sources is a significant undertaking,” said John Poikonen, PharmD, Director of Clinical Informatics at UMass Memorial Medical Center. “Symedical has proven to be a pragmatic and efficient tool that allows us to focus on accuracy.”

Providing the highest quality of care requires access to a consistently accurate representation of the patient’s clinical context. Symedical™ enables clinical applications to maintain the continuity of meaning by sharing patient information as actionable discrete data. “It is no longer enough to offer read only access to medical records stored in various places throughout the healthcare enterprise,” said Charlie Harp, Chief Executive Officer of Clinical Architecture. “We’re pleased to be working with UMass Memorial as they leverage Symedical to deliver a more meaningful and actionable information exchange.”

About Clinical Architecture

Clinical Architecture specializes in meeting the integration and interoperability needs of healthcare through niche consulting and application development. The company was formed around the extensive clinical integration experience of its staff and has consistently succeeded in addressing complex problems with effective pragmatic solutions. The company is located just north of Indianapolis in Carmel, Indiana. For additional information on Clinical Architecture, contact John Wilkinson at (317) 580-8417 or visit www.clinicalarchitecture.com. Informative discussions of interoperability topics are available at the company’s Healthcare IT Blog; www.clinicalarchitecture.com/healthcare_technology_informatics_blog/.

About UMass Memorial Health Care

UMass Memorial Health Care is Central Massachusetts’ largest not-for-profit health care delivery system, covering the complete health care continuum with UMass Memorial Medical Center, its academic medical center, member and affiliated community hospitals, freestanding primary care practices, ambulatory outpatient clinics, home health agencies, hospice programs, a rehabilitation group and mental health services. UMass Memorial is the clinical partner of the University of Massachusetts Medical School. Visit www.umassmemorial.org for additional information. Follow UMass Memorial on Twitter at http://twitter.com/umassmemorial.

IRVING, TX–(Marketwire – August 2, 2010) – VHA Inc., the national health care network, will showcase its VHA SupplyLYNX™ portal and its array of analytics offerings at the annual meeting of the Association for Healthcare Resource & Materials Management Conference on August 1-4, in Denver.

VHA SupplyLYNX offers hospitals the ability to analyze every aspect of their purchasing activities for both products and services and gives them the data they need to accelerate the pace at which hospitals can reduce spending and maximize contract savings.

“VHA SupplyLYNX enables hospitals to fully optimize data throughout the organization and delivers unparalleled insight into the hospital’s performance,” said Scott Downing, executive vice president, Supply Chain Management at VHA. “Cost reduction is a daily focus and is essential to offset anticipated cuts in Medicare reimbursement that will decrease hospital revenues and potentially stifle the bottom line.”

In addition to the recently introduced VHA SupplyLYNX Web portal, attendees can participate in demonstrations of VHA PriceLYNX™ 2.0, the industry’s leading price benchmarking service. VHA PriceLYNX provides benchmarking analysis that arms decision makers with factual information that enables the organization to view long- and short-term market trends and respond to immediate price fluctuations. Ultimately, this information better equips the purchasing team during vendor negotiations. From January 2009 through June 2010, members using VHA PriceLYNX have identified an average savings of $4 million per quarter. 

AHRMM marks the public debut of VHA PriceLYNX mobile. VHA anticipates that mobile access via devices such as smart phones will give hospital personnel the opportunity to make faster decisions when it comes to switching products or accessing lower pricing on the products they already purchase. VHA recently launched its VHA SupplyLYNX mobile platform, built in conjunction with McLean, Va.-based MicroStrategy, to provide mobile access to its suite of analytical products and services. 

“Beginning with our leadership around data standards and e-commerce in 2001, VHA has led other analytics competitors by providing accurate, timely and actionable supply chain information to members, backed by the largest data set in health care,” continued Downing. “What sets us apart is our core belief in price transparency, a data warehouse that provides superior accuracy and a categorization methodology that ensures quality reporting every time.”

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 28,000+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

GILBERT, AZ–(Marketwire – August 2, 2010) – As your boss reminds you that this is your third sick day in two months due to your “back pain excuse,” you hang up the phone frustrated. You aren’t playing hooky. You’d honestly rather be at work than flat on your back in pain. But taking painkillers makes it hard for you to function properly — and it merely masks the pain, instead of solving the problem. If only there was a solution that didn’t involve a knife and more time off work.

“When I treat patients with the one-two punch of spinal decompression and deep tissue laser therapy, they are able to return to their favorite activities, such as gardening, walking, dancing and tennis,” says Brian Self, D.C., a chiropractor with Arizona Pain & Wellness Centers. “And with 6.5 million people stuck in bed each day because of back pain, literally millions could benefit from this affordable, effective, permanent pain relief. While both procedures require multiple visits, most patients feel relief from their pain after their first few sessions.”

Spinal decompression is a revolutionary new technology that treats the symptoms of disc herniations, disc degeneration, sciatica and low back and neck pain. Patients simply lie on their backs while a specialized belt is placed comfortably around their waist. An advanced computer system is then set to focus on each patient’s specific problem area. As disc bulges or herniations are drawn in, or as the discs begin to regenerate, pressure is taken off the nerves and surrounding structures relieving the patient of pain and inflammation. In fact, Dr. Self says that the spinal decompression treatments are so gentle; he’s had patients become so relaxed, they fall asleep during it.

Most patients undergoing spinal decompression will also receive deep tissue laser therapy; because Dr. Self has found that these two treatments work best in tandem. “Our deep tissue laser works by flooding the tissues with photons, energizing the damaged cells and increasing circulation to the painful area,” he says. “This produces a cascade of healing responses in your body, reducing inflammation, thereby reducing or even eliminating your pain. There are no known side effects, it’s noninvasive and nonsurgical — and treatment simply feels like a deep, gentle warmth.”

To put an end to your neck and back pain without medications, injections or surgery, visit www.arizonapainandwellness.com

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 30, 2010) –  Increased demand for testing, new technologies and emerging markets have trumped the economic situation in the world in vitro diagnostics (IVD) market, according to the seventh edition of Kalorama Information’s biennial report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” The healthcare market research publisher reported a $44.3 billion market in 2009, and expects growth to be at a rate of six percent for the next five years. 

According to Kalorama the market has already weathered price declines and as a result developed innovative technologies and approaches. This has dulled the impact of a recession which has hurt other industries. Digital pathology, multiplex assays, automation and test service commercialization represent areas where the industry has developed new approaches. The market changes described in the report were on display at the American Association for Clinical Chemistry (AACC) convention in Anaheim, CA this week.

“The convention reflected what we’ve said in the report; that despite economic hard times, the IVD industry is on an upswing,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and author of the study. “A number of world events bode well for the future of testing.”

Trends such as the use of biomarkers and molecular approaches to testing have only increased since the last edition of the report. Consolidation has been a factor in an industry that is dominated by Roche, Siemens, and Abbott. The report notes that 72 percent of the revenue in 2009 was earned by just 18 companies. This hasn’t stopped scores of new companies with unique approaches from competing in diagnostics, according to Kalorama.

The report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition,” has more information on segment market sizes, forecasts, company analyses, and test product development. The report can be found at Kalorama Information at: http://www.kaloramainformation.com/redirect.asp?progid=79398&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

OAKBROOK TERRACE, IL–(Marketwire – July 30, 2010) –  Each year, millions of people — from elderly nursing home residents to hospitalized children to women who have just given birth — are injured by falls in health care facilities and homes. The Joint Commission today launched a national campaign to help Americans reduce the risk of falling.

The new education campaign, which is part of The Joint Commission’s award-winning Speak Up™ program, recognizes that falls are a serious problem. Statistics from the Centers for Disease Control and Prevention (CDC) show that falls are the second leading cause of injury-related deaths for people ages 65 and older, and are the most common cause of injuries and hospital admissions among the elderly. (Source: CDC, NCHS. Mortality Data Tapes. Hyattsville, MD: the Center, 1998.) Reducing injuries, disabilities and deaths from falls has even been included as part of the Healthy People 2010 program. The national Healthy People 2010 objectives from the U.S. Department of Health and Human Services identify the most significant preventable threats to health and establish national goals to reduce these threats.

“Falls can cause serious to life-threatening injuries; however, there are steps people can take at home or in a health care facility to reduce their risk of falling. We want people to be aware of these simple yet important precautions and avoid preventable injuries,” says Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission.

The new Speak Up™ campaign offers tips and actions that will help people reduce the risk of falling, whether at home or in a medical facility. Among the topics are:

• Taking care of your health — this includes exercise to improve strength and balance, staying hydrated, having an eye exam regularly and talking to your doctor about any side effects from medications that might cause drowsiness or confusion.
• Taking extra precautions — simple actions such as turning on the lights when entering a room, keeping walkways clear, using handrails on stairs, and wearing proper shoes can make a difference.
• Making small changes to your home — using motion sensors or timers for lights, placing nightlights in bedrooms and bathrooms, removing throw rugs, and applying non-slip decals on stairs and in bathtubs to reduce the risk of falls. Home care agencies, personal care and support agencies, or community programs may be available to help you accomplish these tasks if you are older or disabled.
• Taking extra precautions in the hospital or nursing home, for example, people in health care facilities should use the call button to ask for help to get out of bed or go to the bathroom, wear non-slip socks, lower the height of the bed and bed rails, and tell the nurse or doctor if medicine is making you feel dizzy or sick.

The framework of the Speak Up™ program urges patients to:

• Speak up if you have questions or concerns, and if you don’t understand, ask again. It’s your body and you have a right to know.
• Pay attention to the care you are receiving. Make sure you’re getting the right treatments by the right health care professionals. Don’t assume anything.
• Educate yourself about your diagnosis, the medical tests you are undergoing, and your treatment plan.
• Ask a trusted family member or friend to be your advocate.
• Know what medications you take and why you take them. Medication errors are the most common health care errors.
• Use a hospital, clinic, surgery center, or other type of health care organization that has undergone a rigorous on-site evaluation against established state-of-the-art quality and safety standards, such as that provided by The Joint Commission.
• Participate in all decisions about your treatment. You are the center of the health care team.

Speak Up™ brochures also are available on preventing errors in medical care for children, finding pain relief, understanding caregivers, understanding medical tests, recovering after leaving the hospital, preventing medication mistakes, preventing infections, preparing to become a living organ donor, avoiding wrong site surgery and preventing errors in care. Brochures can be found at http://www.jointcommission.org/PatientSafety/SpeakUp/. All of the Speak Up™ brochures are available in an easy-to-read format and in Spanish.

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission evaluates and accredits more than 17,000 health care organizations and programs in the United States, including more than 9,500 hospitals and home care organizations, and more than 6,300 other health care organizations that provide long term care, behavioral health care, laboratory and ambulatory care services. In addition, The Joint Commission also provides certification of more than 1,000 disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for-profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_00728_Fall_Prevention/index.html

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – July 30, 2010) –  Bederra Corporation (PINKSHEETS: BEDA) management announced that the company has attained Pinksheet Current Information status on otcmarkets.com. Management had previously announced its intention to satisfy the “Alternative Reporting Standard” of public transparency in the company’s efforts to further investor relations and voluntarily make adequate and current information publicly available.

Management also noted that it remains currently in discussions with several potential acquisition candidates both in the medical area and outside this market. While the company remains dedicated to further growth in the medical services industry, management had recently announced its decision to explore diversification options in the interest of shareholders until further information regarding the overall direction of the recently passed healthcare legislation is announced. 

About Bederra Corp.
http://www.bederra.com
Bederra Corporation provides multiple modality diagnostic medical services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 30, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today reported its financial results
for the six months ended June 30, 2010 and provided a business update on
its activities.

Michele Garufi, Chairman and CEO of NicOx, declared: “This has been both an
active and a challenging first half for NicOx, as we worked with regulators
in the United States and Europe on the marketing applications for
naproxcinod. We will collaborate closely with both regulatory authorities
in the coming months. We will also focus on securing potential licensing
agreements for naproxcinod in Europe and the rest of the world, ensuring
the continued success of our existing partnerships and prioritizing our
research programs. We will continue to manage our cash resources in the
most cost-effective manner to ensure the future growth of the Company
whilst also pursuing appropriate in-licensing and M&A opportunities.”

Key events of the first six months of 2010:

– NicOx and Bausch + Lomb signed a Worldwide Licensing Agreement for the
glaucoma candidate NCX 116

– The European Medicines Agency (EMA) validated the Marketing Authorization
Application (MAA) for naproxcinod

– Joint Advisory Committee of the U.S. Food and Drug Administration (FDA)
voted that they did not have sufficient evidence to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis

– Additional clinical data for naproxcinod and preclinical results for NCX
434 and NCX 1236, two of the Company’s nitric oxide (NO)-donating New
Molecular Entities, were presented at scientific and medical conferences

– NicOx and TOPIGEN Pharmaceuticals Inc. mutually terminated their
collaboration for TPI 1020 as a result of the acquisition of TOPIGEN

Post reporting period:

– On July 22, 2010, NicOx announced the receipt of a Complete Response
Letter from the U.S. Food and Drug Administration (FDA), stating that it
could not approve the New Drug Application (NDA) for naproxcinod. NicOx
plans on discussing the Complete Response Letter and potential next steps
with the FDA, as early as possible.

Eric Castaldi, Chief Financial Officer of NicOx, declared: “NicOx has a
strong cash position, with no long-term debt and cash and cash equivalents
totaling ?128.4 million at the end of June 2010. We will continue to
ensure careful conservation of our funds.”

Financial summary for the first half of 2010:

Revenues for the first half of 2010 were ?7.4 million, compared to
?1.1 million during the same period in 2009. These revenues correspond
to the initial license payment received from Bausch + Lomb in the first
quarter of the year, as per the agreement signed in March 2010.

For the first six months of 2010, operating expenses were ?36.4
million, compared to ?32.7 million for the same period in 2009. These
expenses correspond principally to personnel costs related to the
regulatory processes for naproxcinod both in the United States and in
Europe, investments in naproxcinod’s supply chain and costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA.

NicOx recorded a total net loss for the period of ?27.5 million for
the first six months of 2010, compared to a corresponding net loss of
?27.2 million for the same period in 2009. On June 30, 2010, NicOx had
cash and cash equivalents of ?128.4 million, compared to ?148.3
million on December 31, 2009.

Review of the first six months of 2010:

Signature of a Worldwide Licensing Agreement with Bausch + Lomb

In March 2010, NicOx and Bausch + Lomb signed a Worldwide Licensing
Agreement granting Bausch + Lomb exclusive rights to develop and
commercialize NCX 116, an NO-donating prostaglandin F2-alpha analog for the
potential treatment of glaucoma and ocular hypertension. Both companies
have already held an initial meeting to agree on the next steps for the
development of NCX 116. Under the terms of this agreement, NicOx received
an initial license payment of $10 million and stands to receive potential
milestones totaling $169.5 million, as well as tiered double-digit
royalties on the sales of NCX 116.

Regulatory status of naproxcinod in the United States

A Joint Advisory Committee of the FDA, including the Arthritis Drugs
Advisory Committee and the Drug Safety and Risk Management Advisory
Committee, voted by 16 to 1 with 1 abstention on May 12, 2010 that they did
not have sufficient evidence at that time to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis.

On July 22, 2010, NicOx announced the receipt of a Complete Response Letter
from the U.S. Food and Drug Administration (FDA) related to the New Drug
Application (NDA) for naproxcinod. The FDA informed NicOx that its review
of the NDA was complete and that it did not approve the naproxcinod
application. The FDA recommended conducting one or more long-term
controlled studies to assess the cardiovascular and gastrointestinal safety
of naproxcinod. Additional studies to demonstrate a clinically meaningful
therapeutic benefit attributable to the nitric oxide donation were also
recommended. No clinical efficacy studies were requested. NicOx plans to
discuss the Complete Response Letter and potential next steps as early as
possible with the FDA.

Regulatory status of naproxcinod in Europe

In January 2010, the European Medicines Agency (EMA) validated the
Marketing Authorization Application (MAA) for naproxcinod, which was
submitted through the centralized procedure in December 2009. NicOx is
seeking approval for an indication for the relief of the signs and symptoms
of primary osteoarthritis. The Medicinal Products for Human Use (CHMP)
opinion is expected by mid-2011, the exact timing depending on the
interactions needed with the health authorities in the last phase of the
review process.

Presentation of scientific results for naproxcinod

Detailed results from the 301 study were published in the May issue of
Osteoarthritis and Cartilage. Additional clinical data for naproxcinod were
presented in May at the American Society of Hypertension Annual Scientific
Meeting and Exposition in New York and in June at the European Meeting on
Hypertension in Olso and the Annual European Congress of Rheumatology in
Rome.

Presentation of promising preclinical results in international conferences

Preclinical results obtained with two of NicOx’s NO-donating New Molecular
Entities (NMEs) were presented in congresses in the first half of 2010. In
May, preclinical findings obtained with NCX 1236, a lead compound for the
potential treatment of Neuropathic Pain, were presented at the
International Congress on Neuropathic Pain in Athens. Preclinical results
for NCX 434, a potential preclinical candidate in Diabetic Macular Edema
(DME), were presented in May at the Ocular Diseases & Drug Discovery
conference in Boston and in June at the Retina International World Congress
in Stresa.

Review of the consolidated financial results for the six months ended June
30, 2010 and 2009:

Revenues

NicOx’s revenues totaled ?7.4 million for the six months ended June
30, 2010 compared to ?1.1 million for the six months ended June 30,
2009.

This significant increase results from the recognition as revenues during
the first quarter of 2010 of ?7.4 million corresponding to the initial
license payment received from Bausch + Lomb following the signature of a
licensing agreement in March 2010 that granted Bausch + Lomb exclusive
worldwide rights to develop and commercialize NCX 116. This amount has been
immediately recognized in revenues because the Company will not have
continuing involvement in the future development of the compound which is
subject of this collaboration agreement. No revenues have been recorded in
the second quarter of 2010.

Operating expenses

For the six months ended June 30, 2010, operating expenses totaled
?36.4 million, compared to ?32.7 million for the six months ended
June 30, 2009, of which, 74% was attributable to research and development
expenses and 26% attributable to selling and administrative expenses in the
first semester of 2010, compared to 77% and 23% respectively in the first
semester of 2009.

Research and development expenses were ?26.9 million during the first
semester of 2010, compared to ?25.1 million during the first semester
of 2009 (including ?0.1 million allocated to cost of sales in 2009
corresponding to the expenses incurred by NicOx in performing research
activities under the contract signed with Pfizer). In the first semester of
2010, research and development expenses correspond principally to personnel
expenses related to the activities performed in relation with the
naproxcinod New Drug Application and Marketing Authorization Application
submitted respectively in the US and in Europe and to investment expenses
in dedicated manufacturing facilities of its active ingredient supplier DSM
in order to increase the naproxcinod supply chain capacity and flexibility.
Following the decision in July 2010 of the FDA not to approve the marketing
application for naproxcinod in the US, indemnities in an amount of
?6.9 million have been booked as research and development expenses in
the accounts as of June 30, 2010, to be paid to suppliers involved in the
manufacturing of naproxcinod for the anticipated cancellation of purchase
orders. The Company employed 79 people in research and development on June
30, 2010, compared to 93 people at the same date in 2009.

General and administrative expenses were ?3.2 million in the first
semesters of 2010 and 2009 and include personnel expenses in administrative
and financial functions, as well as the remuneration of corporate officers,
including stock option, free share and warrant attributions. Selling and
corporate development expenses totaled ?6.2 million during the first
six months ended June 30, 2010 compared to ?4.4 million during the
same period in 2009 and correspond to market research and analysis
activities for naproxcinod, as well as the business development and
communication activities of the Company. The Company employed 48 people in
its selling, general and administrative departments on June 30, 2010,
compared to 39 people on June 30, 2009.

Other income

Other income totaled ?1.6 million during the first semester of 2010
compared to ?3.1 million in the first semester of 2009. Other income
corresponds mainly to the operational subsidies from the research tax
credits in France and in Italy.

Operating result

The operating loss amounted to ?27.4 million in the six months ended
June 30, 2010, compared to ?28.5 million in the same period in 2009.

Other results

Net financial income totaled ?0.1 million during the first semester of
2010, compared to ?1.3 million during the first semester of 2009, and
represents mainly the returns on the financial investments of the Company’s
cash, cash equivalents.

The income tax expense incurred by NicOx during the first six months of
2010 relates to tax from its US and Italian subsidiaries and totaled
?0.3 million, compared to ?0.1 million during the same period in
2009.

Total net loss of the period

The total net loss for the period was ?27.5 million on June 30, 2010,
compared to ?27.2 million on June 30, 2009. Notwithstanding the strong
increase of the revenues recognized in the first six months of 2010
following the initial license payment received from Bausch + Lomb, the
total net loss on June 30, 2010 remains at the same level as last year due
to the impact of the anticipated cancellation of manufacturing and pre-
commercial activities related to naproxcinod following the decision of the
FDA not to approve the application of the product in the United States.

Consolidated statement of financial position

The indebtedness incurred by NicOx is mainly short-term operating debt. On
June 30, 2010, the Company’s current liabilities totaled ?16.6
million, including ?12.0 million in accounts payable to suppliers and
external collaborators (including ?5.9 million with respect to the
cancellation of orders of naproxcinod active drug substance), ?2.5
million in accrued compensation for employees, ?1.9 million in other
contingencies and liabilities (corresponding to the costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA) and ?0.2 million for
other liabilities.

The Company’s cash and cash equivalents were ?128.4 million on June
30, 2010, compared to ?148.3 million on December 31, 2009, and
?76.8 million on June 30, 2009. In late 2009, the Company completed a
two step capital increase and received a total of ?94.6 million
corresponding to the net proceeds of the following operations: ?29.4
million from a private placement of shares to institutional investors
completed on November 23, 2009, and ?65.2 million from a rights issue
completed on December 23, 2009.

NicOx will continue to pursue the European regulatory process for
naproxcinod and follow-up with the FDA after the Complete Response Letter.
NicOx will actively seek to enter into partnerships for naproxcinod. The
Company’s cash position is strong and NicOx is taking all necessary steps
to preserve it.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. For a discussion of
risks and uncertainties which could cause actual results, financial
condition, performance or achievements of NicOx S.A. to differ from those
contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risque”) section of the Document de Reference filed
with the AMF, which is available on the AMF website (http://www.amf-
france.org) or on NicOx S.A.’s website (http://www.nicox.com).

+-------------------------+-+--------------------+-+---------+
|                         | |For the period ended| |         |
|                         | |June 30,            | |         |
+-------------------------+-+--------------------+-+---------+
|                         | |2010                | |    2009 |
+-------------------------+-+--------------------+-+---------+
|                         | |(in thousands of EUR| |         |
|                         | |except for per share| |         |
|                         | |data)               | |         |
+-------------------------+-+--------------------+-+---------+
|Revenues                 | |7,423               | |   1,119 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Cost of sales            | |-                   | |    (75) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Research and development | |(26,924)            | |(25,031) |
|expenses                 | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Administrative expenses  | |(3,214)             | | (3,234) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Selling expenses         | |(6,241)             | | (4,403) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other income             | |1,600               | |   3,130 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Operating loss           | |(27,356)            | |(28,494) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance income           | |183                 | |   1 388 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance expense          | |(70)                | |    (54) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Loss before income tax   | |(27,243)            | |(27,160) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Income tax expense       | |(257)               | |    (77) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Net loss of the          | |(27,500)            | |(27,237) |
|period                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Exchange differences on  | |(38)                | |     (1) |
|translation of foreign   | |                    | |         |
|operations               | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other comprehensive      | |(38)                | |     (1) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Total comprehensive      | |(27,538)            | |(27,238) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Attributable to:         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Equity holders of the  | |(27,538)            | |(27,238) |
|parent                   | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Non-controlling        | |-                   | |       - |
|interests                | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Basic and diluted loss   | |(0.38)              | |  (0.57) |
|per share attributable to| |                    | |         |
|equity holders of the    | |                    | |         |
|parent                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+

+----------------------+--------------------+-+------------------+--------+
|                      |   June 30, 2010    | |December 31, 2009 |        |
+----------------------+--------------------+-+------------------+--------+
|                      |(in thousands       | |                  |        |
|                      | of EUR)            | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|ASSETS                |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current assets    |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Property, plant &     |              2,782 | |                  |  2,772 |
|equipment             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Intangible assets     |                794 | |                  |    797 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |                936 | |                  |    477 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other financial assets|                267 | |                  |    238 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                  - | |                  |    156 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,779 | |                  |  4,440 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current assets        |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |              3,263 | |                  |  2,597 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other current assets  |                988 | |                  |  1,329 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Prepaid expenses      |              1,213 | |                  |    784 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Cash and cash         |            128,448 | |                  |148,275 |
|equivalents           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current assets  |            133,912 | |                  |152,985 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL ASSETS          |            138,691 | |                  |157,425 |
+----------------------+--------------------+-+------------------+--------+
|EQUITY AND LIABILITIES|                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Common shares         |             14,505 | |                  | 14,434 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other reserves        |            103,046 | |                  |128,444 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-controlling       |                  - | |                  |      - |
|interests             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total Equity          |            117,551 | |                  |142,878 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current           |                    | |                  |        |
|liabilities           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              4,369 | |                  |  4,069 |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                 98 | |                  |     91 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 44 | |                  |      6 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,511 | |                  |  4,166 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current liabilities   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              1,890 | |                  |      - |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 18 | |                  |      7 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Trade payables        |             12,034 | |                  |  6,136 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current income tax    |                  - | |                  |     19 |
|payable               |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Social security and   |              2,504 | |                  |  3,909 |
|other taxes           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other liabilities     |                183 | |                  |    310 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current         |             16,629 | |                  | 10,381 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL EQUITY AND      |            138,691 | |                  |157,425 |
|LIABILITIES           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|NicOx S.A.,           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Les Taissounières-Bât |                    | |                  |        |
|HB4 - 1681 route des  |                    | |                  |        |
|Dolines - BP313, 06906|                    | |                  |        |
|Sophia Antipolis cedex|                    | |                  |        |
|France.               |                    | |                  |        |
|Tel.                  |                    | |                  |        |
|+33 (0)4 9724 53 00   |                    | |                  |        |
|Fax                   |                    | |                  |        |
|+33 (0)497 24 53 99   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
+----------------------+--------------------+-+------------------+--------+

This information is provided by HUGIN

SAN DIEGO, CA–(Marketwire – July 29, 2010) –  Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, titled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59,” was published in the journal Xenotransplantation as a collaboration between Medistem and the Institute of Organ Transplantation, Tongji Hospital, in Wuhan, China.

The study found that CD59, a molecule made by ERC, plays an important role in protecting cells from immune rejection when placed in contact with immune components from another species. The ERC is a mesenchymal-like stem cell that Medistem discovered in 2007 capable of generating heart, lung, brain, muscle, blood vessel, pancreas, liver, fat and bone tissue. The original description of this cell, which won the “Publication of the Year Award” may be found at http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf.

“One of the fundamental aspects of Medistem’s lead product, the Endometrial Regenerative Cell (ERC), is its ability to function without the need for tissue matching. In other words, the ERC stem cells act as universal donors. We have previously published that human ERC are effective in treating mice having a condition that resembles critical limb ischemia (see paper http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf). We now believe that expression of the molecule CD59 on ERC may be one of the mechanisms by which these human cells can be used not only as a universal donor for humans, but also for the treatment of numerous diseases across a variety of animal species,” said Thomas Ichim, CEO of Medistem.

Medistem has filed an IND with the FDA for treatment of critical limb ischemia (severe obstruction of the arteries that leads to decreased blood flow to the extremities) with ERC. Currently the company is in the process of completing additional experiments requested by the FDA before clinical trials can commence. Through physician-initiated compassionate use mechanisms Medistem has already published on human use of ERC in treatment of heart failure, Duchenne Muscular Dystrophy, and multiple sclerosis. A recent peer-reviewed paper describing ERC in treatment of heart failure may be found at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

MADISON, WI–(Marketwire – July 29, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), producer of the Hi*Art® treatment system and other products for
advanced radiation therapy, today released financial results for the second
quarter ended June 30, 2010.

Second Quarter Results

Second quarter 2010 revenue was $47.6 million, an increase of 16% from
$41.1 million in the second quarter of 2009. Revenue from product sales
was $34.2 million in the second quarter of 2010, up 12% compared to the
same quarter last year, and revenue from service and other was $13.4
million in the second quarter of 2010, up 27% compared to the same quarter
last year. The company reported a second quarter 2010 loss from operations
of $8.4 million, a 14% decrease from the $9.7 million loss from operations
for the same period last year.

The company incurred a net loss attributable to shareholders of $6.9
million, or $0.13 per share, for the second quarter of 2010, compared to a
net loss of $7.1 million, or $0.14 per share, for the second quarter of
2009.

As of June 30, 2010, the company had $145.7 million of cash, cash
equivalents and short-term investments, representing a $3.0 million
decrease from March 31, 2010, and minimal debt. During the quarter, there
were no borrowings against the company’s credit facility.

As of June 30, 2010, the company had a revenue backlog of $139.2 million, a
4% increase from the $134.2 million backlog as of March 31, 2010. The
backlog includes $42.5 million of equipment orders received during the
second quarter of 2010. One order was removed from backlog during the
second quarter due to uncertainty surrounding the project schedule.
Backlog includes only firm orders that the company believes are likely to
ship within the next two years. Backlog does not include any revenue from
service contracts, which represents a growing portion of the company’s
overall revenue.

“Our second quarter financial results were in line with our internal
expectations and represent a solid improvement over the same period last
year,” said Fred Robertson, TomoTherapy’s CEO. “In addition, we are
pleased with the 13% increase in revenue from the first quarter of 2010 and
the $5.0 million net increase to our backlog since March 31, 2010.
Specifically, we realized a rise in new orders, which we believe reflects
the strength of our new product offerings as well as enhanced global sales
and marketing efforts. On the service side, revenue increased
significantly compared to the same period last year, due to continued
growth in the number of service contracts, and we again achieved strong
customer service rankings. We continue to take steps to enhance our
financial performance and drive toward profitability while still investing
in key product development initiatives. Importantly, our capital position
remained strong in the quarter despite the continuing challenges in the
global economy.”

Six-Month Results

For the six months ended June 30, 2010, revenue was $89.7 million, a 25%
increase from $71.7 million for the six months ended June 30, 2009.
Revenue from product sales was $63.5 million in the first half of 2010, up
23% compared to the first half of 2009, and revenue from service and other
was $26.2 million in the first half of 2010, up 31% compared to the first
half of 2009.

The company reported a year-to-date 2010 loss from operations of $14.4
million, a 39% decrease from the loss from operations of $23.7 million
during the first six months of 2009. The company incurred a net loss
attributable to shareholders of $11.6 million, or $0.22 per share, for the
six months ended June 30, 2010, compared to a net loss attributable to
shareholders of $20.1 million, or $0.40 per share, for the same period last
year.

During the first half of 2010, the company’s cash, cash equivalents and
short-term investments decreased by $8.7 million. The company’s backlog
increased by $3.4 million during the first half of 2010, from $135.8 as of
December 31, 2009 to $139.2 million as of June 30, 2010.

Outlook

The company reaffirms its revenue and earnings guidance for full-year 2010.
Management still expects 2010 revenue to be comparable to 2009 revenue of
$160 million to $180 million, with a net loss attributable to shareholders
in the range of $0.65 to $0.85 per share. Consistent with prior years,
management is not providing specific quarterly guidance. However, similar
to 2009, management anticipates that the timing of expected customer
deliveries will result in 2010 second half revenues being heavily weighted
toward the fourth quarter.

Robertson concluded, “Given our second quarter performance and expectations
for the balance of the year, we remain on track to deliver results in line
with our previously announced guidance. While there is still uncertainty
with respect to macro conditions, particularly in Europe, we are encouraged
by recent performance in North America and Asia. We also continue to make
good progress on several key initiatives, including diversifying our
product line-up and expanding our business both in North America and other
global markets. With significant interest in our TomoDirect™ and
TomoHD™ offerings, entry into new markets, and greater access to many
hospitals through new strategic Group Purchasing Organization agreements,
we believe TomoTherapy is well positioned to capitalize on the substantial
opportunity in the growing global radiation therapy market.”

Investor Conference Call

TomoTherapy will conduct a conference call regarding its second quarter
2010 results at 5:00 p.m. EDT today, July 29, 2010 (4:00 p.m. CDT). To
hear a live Webcast or replay of the call, visit the Investor Relations page at TomoTherapy.com, where it will
be archived for two weeks. To access the call via telephone, dial
1-800-260-8140 from inside the United States or
1-617-614-3672 from outside the United States, and enter pass code
35309628. The replay can be accessed by dialing 1-888-286-8010 from inside
the United States or 1-617-801-6888 from outside the United States and
entering pass code 64325104. The telephone replay will be available
through 11:59 p.m. CDT on August 5, 2010.

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation
therapy solutions that can be used to efficiently treat a wide variety of
cancers, from the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding healthy
tissue. TomoTherapy’s suite of solutions includes its flagship Hi*Art®
treatment system, which has been used to deliver more than three million
CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment
fractions; the TomoHD™ treatment system, designed to enable cancer centers
to treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to improve
access and availability of state-of-the-art cancer care. TomoTherapy’s
stock is traded on the NASDAQ Global Select Market under the symbol “TOMO.”
To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements
concerning market acceptance of the company’s technology; growth drivers;
the company’s orders, revenue, backlog or earnings growth; future financial
results and any statements using the terms “should,” “believe,” “outlook,”
“expect,” “anticipate” or similar statements are forward-looking statements
that involve risks and uncertainties that could cause the company’s actual
results to differ materially from those anticipated. Such risks and
uncertainties include: demand for the company’s products; impact of sales
cycles and competitive products and pricing; the effect of economic
conditions and currency exchange rates; the company’s ability to develop
and commercialize new products; its reliance on sole or limited-source
suppliers; its ability to increase gross margins; the company’s ability to
meet U.S. Food and Drug Administration (FDA) and other regulatory agency
product clearance and compliance requirements; the possibility that
material product liability claims could harm future revenue or require the
company to pay uninsured claims; the company’s ability to protect its
intellectual property; the impact of managed care initiatives, other health
care reforms and/or third-party reimbursement levels for cancer care;
potential loss of key distributors or key personnel; risk of interruptions
to the company’s operations due to terrorism, disease or other events
beyond the company’s control; and the other risks listed from time to time
in the company’s filings with the U.S. Securities and Exchange Commission,
which by this reference are incorporated herein. TomoTherapy assumes no
obligation to update or revise the forward-looking statements in this
release because of new information, future events or otherwise.

                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share data)
                                (unaudited)



                                 Three Months Ended     Six Months Ended
                                      June 30,              June 30,
                                --------------------  --------------------
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------

Revenue:
 Product                        $  34,242  $  30,552  $  63,471  $  51,685
 Service and other                 13,388     10,528     26,239     20,018
                                ---------  ---------  ---------  ---------
  Total revenue                    47,630     41,080     89,710     71,703
                                ---------  ---------  ---------  ---------
Cost of revenue:
 Product                           17,354     14,253     30,139     25,998
 Service and other                 17,818     18,312     34,509     34,651
                                ---------  ---------  ---------  ---------
  Total cost of revenue            35,172     32,565     64,648     60,649
                                ---------  ---------  ---------  ---------
   Gross profit                    12,458      8,515     25,062     11,054
                                ---------  ---------  ---------  ---------
Operating expenses:
  Research and development          8,960      7,020     16,500     12,869
  Selling, general and
   administrative                  11,910     11,224     22,944     21,876
                                ---------  ---------  ---------  ---------
   Total operating expenses        20,870     18,244     39,444     34,745
                                ---------  ---------  ---------  ---------
Loss from operations               (8,412)    (9,729)   (14,382)   (23,691)
Other income (expense):
  Interest income                     416        695        947      1,392
  Interest expense                    (12)       (15)       (23)       (29)
  Other expense, net                 (578)      (107)    (1,026)      (363)
                                ---------  ---------  ---------  ---------
   Total other income (expense)      (174)       573       (102)     1,000
                                ---------  ---------  ---------  ---------
Loss before income tax and
 noncontrolling interests          (8,586)    (9,156)   (14,484)   (22,691)
  Income tax expense (benefit)         10       (318)       (34)      (418)
                                ---------  ---------  ---------  ---------
Net loss                           (8,596)    (8,838)   (14,450)   (22,273)
  Noncontrolling interests          1,673      1,715      2,849      2,151
                                ---------  ---------  ---------  ---------
Net loss attributable to
 shareholders                   $  (6,923) $  (7,123) $ (11,601) $ (20,122)
                                =========  =========  =========  =========

Weighted-average common shares
 outstanding -
 basic and diluted                 51,713     50,592     51,640     50,592
                                =========  =========  =========  =========

Loss per common share - basic
 and diluted                    $   (0.13) $   (0.14) $   (0.22) $   (0.40)
                                =========  =========  =========  =========





                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

                  CONDENSED CONSOLIDATED BALANCE SHEETS
                              (In thousands)
                                (unaudited)


                                                    June 30,   December 31,
                                                      2010         2009
                                                  ------------ ------------

                                  ASSETS
Cash and cash equivalents                         $     99,240 $     76,108
Short-term investments                                  46,434       78,225
Receivables, net                                        32,915       33,559
Inventories, net                                        53,204       47,669
Prepaid expenses and other current assets                5,507        3,633
                                                  ------------ ------------
 Total current assets                                  237,300      239,194
Property and equipment, net                             18,198       18,628
Other non-current assets, net                           10,588       12,429
                                                  ------------ ------------
 TOTAL ASSETS                                     $    266,086 $    270,251
                                                  ============ ============

                           LIABILITIES AND EQUITY
Accounts payable                                  $     11,896 $      6,269
Accrued expenses                                        20,273       19,588
Accrued warranty                                         3,776        4,173
Deferred revenue                                        31,506       34,145
Customer deposits                                       11,145       13,266
                                                  ------------ ------------
 Total current liabilities                              78,596       77,441
Other non-current liabilities                            4,404        5,475
                                                  ------------ ------------
 TOTAL LIABILITIES                                      83,000       82,916

Total shareholders' equity                             175,498      183,424
Noncontrolling interests                                 7,588        3,911
                                                  ------------ ------------
 TOTAL EQUITY                                          183,086      187,335

                                                  ------------ ------------
 TOTAL LIABILITIES AND EQUITY                     $    266,086 $    270,251
                                                  ============ ============

WAYNE, PA–(Marketwire – July 29, 2010) –  Clinical and Laboratory Standards Institute (CLSI) unveiled the release of StatisPro^™, its new method evaluation software package for the evaluation, verification, and validation of performance characteristics of laboratory test methods at the AACC/ASCLS Annual Meeting this week.

StatisPro software delivers a feature-rich tool designed to perform the statistical analysis necessary to meet regulatory and accreditation requirements. Hospitals, physician office laboratories, reference laboratories, and customer support departments of in vitro diagnostic manufacturers can benefit from using this new method evaluation software.

David Grenache, PhD, DABCC, FACB, Associate Professor, Department of Pathology, University of Utah, ARUP Laboratories, and beta-tester for StatisPro, says, “The benefits of StatisPro are its ease-of-use and intuitive interface. When validating a new method, replacing equipment, or preparing for accreditation or regulatory inspections, StatisPro makes advanced statistical analysis easier regardless of the size of the laboratory using it.”

Developed in conjunction with Analyse-it^®, StatisPro can produce reports on analytical accuracy, precision, linearity, limit of detection and quantitation, and reference intervals and is entirely based on the most up-to-date CLSI guidelines.

With StatisPro, laboratories can:

• Verify comparability of new methods and systems.
• Ensure comparable results across measuring systems.
• Establish reference intervals or transfer intervals between methods and laboratories.

James Huntington, Co-founder, Analyse-it^®, describes the importance of evaluating and verifying method performance, saying, “Laboratories must ensure method performance is as expected to meet regulatory or accreditation requirements. As the statistics necessary to determine method performance become more complex, software such as StatisPro is essential to ensure accurate, correct, determination of method performance.”

CLSI partnered with Analyse-it because of its excellent reputation and proven experience in creating statistically based software, as well as its similar culture and values to CLSI, explains Glen Fine, MS, MBA, CAE, CLSI Executive Vice President. “Since StatisPro is based on CLSI’s world-renowned best practices, it will inspire user confidence. This is the only software package available that streamlines implementation of CLSI’s latest method evaluation guidelines. StatisPro allows staff of laboratories of any size to produce advanced statistical calculations and display reports quickly and accurately in order to ensure the highest quality patient care,” says Fine. 

StatisPro is available directly from CLSI. For more information, please visit www.StatisPro.org or call 877.477.1888.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information visit the CLSI website at www.clsi.org or call 610.688.0100.

Analyse-it Software, Ltd. formed in 1997 to develop statistical analysis and charting software for Microsoft^® Excel^™, and built its flagship product, Analyse-it, through work with some of the world’s largest in vitro diagnostic companies. Now with more than 20,000 customers, Analyse-it is highly respected in the scientific and research community, and is used and cited in thousands of peer-reviewed published papers. For additional information, visit the Analyse-it website at www.analyse-it.com.

Click here to see all recent news from this company

KELLER, TX–(Marketwire – July 29, 2010) – In less time than it takes for a single lunch hour, employees can learn, for free, how to save a life through Cardiopulmonary Resuscitation (CPR). This because Dallas-based non-profit Mission CPR (www.MissionCPR.org) has launched its “Spend 45 Minutes, Save a Life” initiative offering workplace CPR awareness and basic skills training to area businesses and organizations completely free of charge. Mission CPR has launched this program as part of the American Heart Association’s overriding “CPR Anytime” campaign created to increase the incidence of bystander CPR by making training more accessible.

“A full 93.6 percent of sudden cardiac arrest victims die simply because the vast majority of those witnessing the arrest do not know how to perform CPR and are reluctant to even try,” says Jeff D. Hill, CEO of Mission CPR, whose own life was saved by CPR at age 3 and who has since saved a life using CPR through his work as an EMT. “Our organization aims to not only raise awareness about the vital importance of bystander CPR, but also actually save lives by providing local groups with basic, easily absorbed training in a convenient on-site workplace setting — at no cost to the employee, group member or organization.” 

“The session lasts only 45 minutes and very little time is needed to organize the presentation,” Hill underscores. “This program is an invaluable employee benefit that has nothing but upside for all involved — the company, employee, their families and the Dallas/Fort Worth community at large.”

At the age of 3, Hill’s own life was saved by bystander CPR. Left briefly unattended, he fell in a pool and drowned. Hill had no heartbeat and had stopped breathing completely. A visiting relative heard his mother screaming once she pulled Hill from the pool, and he jumped in to try to help. This relative had received CPR training years before and was unsure if he was “doing it right,” but he TRIED his best, revived Hill’s heartbeat, and kept him alive long enough until the EMS arrived to take over. This experience exemplifies why even the most basic understanding of CPR is important and how those skills can prove critical in an emergency situation.

Hill notes, “The reality is many people in distress that need CPR do not get the help because bystanders are not trained or are afraid to try. Indeed, in my prior work as a firefighter and EMT, most bystanders waited until we arrived to attempt CPR and, most often, it was too late. Even the most basic skills training can give someone the knowledge and confidence needed to attempt CPR until medical professionals arrive, and can mean the difference between life and death.”

In addition to its free “Spend 45 Minutes, Save a Life” training program, Mission CPR also offers interested and key employees full certification-based CPR and First Aid training at a reduced cost, with proceeds used to purchase additional American Heart Association CPR training kits to support and prolong the organization’s free training efforts. Mission CPR sessions are available for company meetings and conferences, “lunch and learns,” health fairs, benefits enrollment periods or any other time that best suits the business or organization. 

Interested parties may visit www.MissionCPR.org to learn more about Mission CPR’s free and reduced-fee certification programs. More information about the American Heart Association’s “CPR Anytime” campaign may be accessed online at http://www.trihealth.com/aus/srv/CPR_Anytime.aspx.

About Mission CPR
Based in Keller, Texas, Mission CPR is a non-profit organization dedicated to raising awareness about the vital importance of bystander CPR in both a local and nationwide effort to save lives. The organization provides free CPR awareness presentations and basic skills training, and reduced-cost CPR and First Aid certifications, to businesses and organizations of all types throughout the Dallas/Fort Worth region. Mission CPR is spearheaded by CPR recipient and survivor Jeff D. Hill who himself, as a former EMT, has saved the life of another using CPR. Contact Mission CPR at 817-509-0004 or [email protected], or learn more about the organization online at www.MissionCPR.org.

Click here to see all recent news from this company

HALIBURTON, ON–(Marketwire – July 29, 2010) – Patient News, a leading dental marketing company in the US and Canada, was recognized for its outstanding newsletter design and layout in the 22nd Annual Awards for Publication Excellence Competition (APEX). Judged by a panel of experienced writers and editors, the APEX 2010 awards are based on excellence in graphic design, editorial content, and the ability to achieve overall communications excellence. Despite an exceptionally intense competition with more than 3,700 entries, Patient News received an Award for Publication Excellency by Apex 2010 for Dr. Randy G. Fussell’s Fall 2009 dental marketing newsletter “Smile! Pass It on!”

“At Patient News we take great pride in our highly skilled editorial, design, and production teams who work together to create engaging, innovative, and personable patient marketing and potential patient marketing materials that speak directly to our clients’ targeted audience,” said Karen Galley, President of Patient News. “As the industry leader, our customized marketing methods are proven, reliable, professional, and diverse.”

Patient News offers a variety of innovative dental marketing products including dental email newsletters, patient newsletters, direct mail newsletters, dental postcards, patient referral cards and patient satisfaction surveys. All products are tailored to help achieve the specific goals of each client. With nearly 20 years of business and over 100 million newsletters and postcards later, Patient News provides health care specialists with measurably effective practice marketing. In addition to the APEX 2010 Award for Publication Excellency, Patient News has received a number of other awards, including Entrepreneur of the Year, Large Business of the Year, and the American Graphic Design Award.

Patient News has been producing dental marketing materials for almost 20 years in North America and the UK. For additional information on dental marketing from Patient News, call 800.667.0268 or visit www.patientnews.com. To read more on this topic, visit: http://www.patientnews.com/pressreleases/dental-marketing-excellency-award.html.

About Patient News:
 Patient News is North America’s most comprehensive and innovative dental marketing solutions provider. Founded in Canada in 1992, the company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom. The company has been named a Top 100 employer for four consecutive years, and has officially added environmental sustainability to its core values within the company vision.
Contact:

Click here to see all recent news from this company

WAYNE, PA–(Marketwire – July 29, 2010) –  Kenexa (NASDAQ: KNXA), a global provider of business solutions for human resources, today announced that a trio of executives from global and regional healthcare-related companies will share their unique perspectives on talent acquisition and employee engagement during the upcoming 2010 Kenexa World Conference. Gina Nardone, Manager of Talent Acquisition for Baxter Healthcare; Kristy Rigot, System Director of Human Resources for Lee Memorial Health System; and Cathy Fraser, Senior Vice President of Human Resources for Tenet Healthcare Corporation will add their voices to the conference, sharing best practices that are changing the face of HR.

In a session titled “The Effective Great Unknown: Global Expansion in a Decentralized Talent Acquisition Organization,” Nardone will focus on Baxter’s global implementation of Kenexa Recruiter® BrassRing, highlighting the company’s specific challenges, including the initial absence of a strong global talent acquisition presence across the organization. Nardone will explain how Baxter has achieved 85% implementation across the organization, with a goal of 100% by the end of 2011. Recommendations on conducting Delta Workshops, language implementation, dealing with HR turnover, working with limited budgets and post-implementation involvement also will be discussed.

Improving recruitment productivity is not about doing things faster and harder. It is about streamlining work process, standardizing, modifying behaviors, optimizing technology and staying focused on key recruitment workforce metrics. During her presentation of “Soar with the Eagles: Improving Recruitment Productivity,” Rigot will provide an overview of Lee Memorial Health System’s focus on performance improvement strategies and goals based on continuous analysis of candidate pipeline, workflow and performance metrics.

In a presentation titled “Achieving Impact by ‘Under-thinking’ Traditional HR,” Fraser will share how textbook HR does not always make sense, describing different thinking in the traditional towers of talent management, performance management, employee engagement, and anti-unionization, tuned at achieving impact. During this intriguing session, Fraser will highlight the importance of context and organizational readiness, with the backdrop of Tenet Healthcare’s business turnaround.

The fifth annual Kenexa World Conference promises to transform HR through outliers, helping organizations move beyond potential to drive business performance. To reveal true human potential to improve business results, companies must identify and nurture high performers and create the right environment for them to thrive. Attendees of the conference will come to understand how the right individuals in the right environment lead to ultimate success.

Happening Tuesday, September 21 through Thursday, September 23, 2010, in Philadelphia, Pa., the Kenexa World Conference will give companies the information they need to transform HR and move from potential to performance. The 2010 Kenexa World Conference will be held at The Sheraton Society Hill Hotel, One Dock Street, Philadelphia, Pa. For more information or to register, visit www.kenexa.com.

About Kenexa
Kenexa® provides business solutions for human resources. We help global organizations multiply business success by identifying the best individuals for every job and fostering optimal work environments for every organization. For more than 20 years, Kenexa has studied human behavior and team dynamics in the workplace, and has developed the software solutions, business processes and expert consulting that help organizations impact positive business outcomes through HR. Kenexa is the only company that offers a comprehensive suite of unified products and services that support the entire employee lifecycle from pre-hire to exit. Additional information about Kenexa and its global products and services can be accessed at www.kenexa.com.

Click here to see all recent news from this company